

Role of DNA methylation in head and neck cancer

Semra Demokan · Nejat Dalay

Received: 28 March 2011 / Accepted: 14 June 2011 / Published online: 9 July 2011
© Springer-Verlag 2011

Abstract Head and neck cancer (HNC) is a heterogeneous and complex entity including diverse anatomical sites and a variety of tumor types displaying unique characteristics and different etiologies. Both environmental and genetic factors play a role in the development of the disease, but the underlying mechanism is still far from clear. Previous studies suggest that alterations in the genes acting in cellular signal pathways may contribute to head and neck carcinogenesis. In cancer, DNA methylation patterns display specific aberrations even in the early and precancerous stages and may confer susceptibility to further genetic or epigenetic changes. Silencing of the genes by hypermethylation or induction of oncogenes by promoter hypomethylation are frequent mechanisms in different types of cancer and achieve increasing diagnostic and therapeutic importance since the changes are reversible. Therefore, methylation analysis may provide promising clinical applications, including the development of new biomarkers and prediction of the therapeutic response or prognosis. In this review, we aimed to analyze the available information indicating a role for the epigenetic changes in HNC.

Keywords Methylation · Epigenetics · Head and neck cancer

Introduction

Head and neck cancer (HNC) is a highly heterogeneous group of malignant diseases and the sixth most frequently observed cancer type in developing countries (Crowe et al. 2002; Ohshima et al. 2005). It reveals different combinations of various sites and disease types which result from sequential genetic changes in multiple intracellular pathways and inherent viral infections. HNC displays serial dysplastic alterations before acquiring invasive characteristics. Tobacco and/or alcohol use are the main etiological factors and play an important role in oral cavity, pharynx, and larynx cancer (Ohshima et al. 2005). Acute laryngitis which can be caused by chronic irritation, inhalation of irritants, viral infections, or allergic reactions may also increase the risk of cancer development (Kumar et al. 2000). The prognosis of the disease varies according to tumor size, local invasion, histology, and grade as well as ethnic origin. These diverse varieties reflect the versatile pathogenesis of the disease. Identification of novel therapeutic targets and new and specific biomarkers for the early detection of HNC could greatly increase the survival rate and might also help as prognostic indicators.

Head and neck carcinogenesis is a multistep and multifactorial complex mechanism containing a variety of genetic and epigenetic abnormalities in DNA repair, signal transduction, apoptosis, angiogenesis, proliferation, differentiation, and cell cycle regulation (Scully et al. 2000). In recent years, the role of epigenetic alterations have been increasingly recognized. Changes in the methylation patterns are one of the most frequent events in human tumors (Jones

S. Demokan · N. Dalay (✉)
Department of Basic Oncology, Oncology Institute,
Istanbul University,
34093 Capa-Istanbul, Turkey
e-mail: ndalay@yahoo.com

and Baylin 2002). Two types of methylation changes are usually observed: Hypermethylation of the CpG islands and global hypomethylation in a variety of tumors. DNA hypomethylation has been associated with the activation of oncogenes and chromosomal instability leading to over-expression of the oncogenes, while DNA hypermethylation is associated with the repression of tumor suppressor genes (TSG) and genomic instability. DNA methylation also plays an important role in tumor initiation and progression (Jones and Baylin 2002; Momparler and Bovenzi 2000). Thus, gene silencing by hypermethylation is an important mechanism that has great promise for therapy and for the discovery of new biomarkers. However, the information on the frequency and specificity of methylation changes is still insufficient. It presents a challenge to identify crucial genes that are susceptible to methylation-induced silencing and are directly associated with the development of HNC. Since HNC is a heterogeneous disease, the methylation status may vary according to clinical characteristics and environmental and genetic factors such as anatomic involvement of tumor (Dikshit et al. 2007; Azarschab et al. 2003), human papilloma virus (HPV) positivity (Bennett et al. 2010; Richards et al. 2009), smoking (Sharma et al. 2010), microsatellite instability (MSI) (Zuo et al. 2009; Demokan et al. 2006; Sengupta et al. 2007; Liu et al. 2003a, b, 2002), and geographic location (Li et al. 2003a, b; Ayadi et al. 2008). Therefore, analysis of the epigenetic changes in genes playing important roles in these vital molecular mechanisms is crucial in order to understand the molecular biology of head and neck carcinogenesis.

Genetic evidence indicates that the majority of squamous HNC originate from hyperplastic fields characterized by higher numbers of proliferating cells and clonal selection (Rubin 2011; Tabor et al. 2002). Almost two thirds of the tumor recurrences following resection occur in these regions (Tabor et al. 2004; Ha and Califano 2003). Clonal selection, divergence, and expression are the basic characteristics of the field development. Molecular evidence including cells harboring mutations of the TSG and recent data on *p53* mutations support the field cancerization theory. The presence of cells with *p53* gene mutations in these fields have also been shown in HNC (Tabor et al. 2001). The genetic changes characterizing these regions can be used to identify individuals at risk of developing cancer (Dakubo et al. 2007). Furthermore, methylation in noncancerous tissues is now considered as a marker for potential cancer risk and previous exposure to certain carcinogenic factors (Nakajima et al. 2008). Knowledge of the methylation status in these regions may enable intervention by using demethylating agents as chemopreventive means (Dakubo et al. 2007). An epigenetic field effect has been first described

by increased aberrant methylation in normal tissue from patients with liver cancer (Kondo et al. 2000). Later studies have unequivocally shown the presence of an epigenetic field for cancerization (Ushijima 2007). Recently, the presence of an epigenetic field for cancerization has also been shown in colon (Shen et al. 2005), breast (Yan et al. 2006), and renal (Arai et al. 2006) cancers.

Recent advances in technology make it possible to analyze DNA methylation by highly sensitive and quantitative methods. For DNA methylation analysis, a variety of different methodologies have been used, almost all of which rely on three different approaches for treating DNA: the action of methylation-specific endonucleases, bisulfite modification of unmethylated cytosines, or immunoprecipitation (IP) of the methylated DNA fragments. Combination of these initial steps with different detection techniques for analysis have resulted in various analytical methods to investigate candidate genes or to study global DNA methylation. The main methodologies used for methylation analysis are summarized in Table 1. Several techniques initially confined to smaller regions of the genome have now been extended to perform analysis of the whole genome. New high-throughput methodologies provide information to characterize methylated sequences at single-base resolution on a genome-wide scale.

Recent studies have shown that hypermethylation of some TSG may be a valuable biomarker (Kim et al. 2006; Demokan et al. 2010; Kaur et al. 2010; Pattani et al. 2010) in different cancer types. Furthermore, results of clinical

Table 1 The main methodologies used in DNA methylation analysis

Sequence-specific methylation
Quantitative methylation-specific PCR (QMSP)
Methylation-sensitive restriction enzyme analysis
Sensitive restriction-multiplex PCR
Combined bisulfite restriction analysis (COBRA)
Bisulfite sequencing
Pyrosequencing
Multiplex ligation-dependent probe amplification (MLPA)
Mass array analysis
Global methylation
Restriction landmark genomic scanning (RGLS)
Arbitrarily primed methylation-sensitive PCR (AP-MSP)
Methylated CpG island recovery assay (MIRA)
Differential methylation hybridization (DMH)
Analysis of intermethylated sites (AIMS)
Methylated DNA immunoprecipitation (MeDIP)
Whole-genome shotgun bisulfite sequencing (WGSBS)

studies using DNA methyltransferase and histone deacetylase inhibitors indicate the potential of epigenetic therapeutics in clinical oncology (Ren et al. 2011; Wagner et al. 2010). The epigenetic changes may help to predict the prognosis and identify individuals who may benefit from the therapy with demethylating agents (Issa et al. 2004).

In this review, we aimed to summarize the present state of knowledge in head and neck carcinogenesis by analyzing the studies investigating the relationship between methylation and HNC. The publications in the literature were retrieved by literature and keyword search using the ISI, PubMed, and Scopus databases to identify the studies relevant to this review. Citations in these publications were also evaluated for their relevance.

Data from analysis of tumor suppressor gene panels

In recent years, most studies have focused on the analysis of promoter methylation of TSG panels playing a role in vital cellular mechanisms via the candidate gene strategy approach (Table 2). In a study among the North American population (Demokan et al. 2010), *KIF1A* and *EDNRB* genes were highly methylated (97% and 98%, respectively) in the primary tumor tissue and salivary rinse samples from patients with squamous cell carcinoma, while normal salivary and normal mucosal samples were minimally methylated. A significant association between *KIF1A* methylation and tumor site was reported. Kaur et al. (2010) found high methylation levels of the *KIF1A*, *EDNRB*, *DCC*, and *p16* genes in Indian patients with oral squamous cell carcinoma (OSCC) and Pattani et al. (2010) have shown that, in salivary samples from patients with premalignant or malignant oral cavity lesions, promoter hypermethylation of the *KIF1A* and *EDNRB* genes was associated with malignancy. The endothelin receptor type B (*EDNRB*) is a G protein-coupled receptor which activates a phosphatidylinositol–calcium second messenger system (Smollich and Wülfing 2008). The kinesin family member 1A (*KIF1A*) gene encodes a protein that is a microtubule-dependent molecular motor involved in important intracellular functions such as organelle transport and cell division (Okada et al. 1995).

We have evaluated the epigenetic changes specific to head and neck squamous cell carcinoma (HNSCC) by investigating promoter hypermethylation of a panel of 24 TSG via candidate gene approach in a recent study (Yalniz et al. 2011). *CHFR*, *RAR β* , *DAPK1*, and *RASSF1A* genes were found to be the most frequently methylated genes in HNC tumor tissue by methylation-specific multiplex ligation-dependent probe amplification. A further

collaborative study analyzing a panel of 22 genes confirmed these findings and found that the *RAR β* , *APC*, and *CHFR* genes were frequently hypermethylated in HNC (Chen et al. 2007).

In another study, six genes were analyzed in patients with HNSCC treated by radiotherapy (de Schutter et al. 2009). The *MGMT* and *TIMP3* genes displayed higher methylation rates. Promoter hypermethylation of the *TIMP3* and *CDH1* genes were significantly associated with better locoregional control (LRC) and overall survival (OS) or disease-free survival (DFS). *TIMP3* methylation highly correlated with *DAPK* methylation, indicating a very strong functional association between these two genes (Nayak et al. 2007). In other gene panel studies, methylation of the *TIMP3*, *CDH1*, *p16*, *MGMT*, *DAPK*, and *RASSF1* genes were observed in HNSCC tumors and paired saliva samples (Righini et al. 2007; Hasegawa et al. 2002; Rosas et al. 2001; Sanchez-Cespedes et al. 2000). A study analyzing promoter methylation of 15 candidate genes (Steinmann et al. 2009) in tumors and matched normal tissue from patients with HNSCC has shown that methylation of the *p16*, *MGMT*, *DAPK*, *RAR β* , *hMLH1*, *CDH1*, *RASSF2*, *RASSF5*, and *MST1* genes was significantly more frequent in the tumors than the normal tissue (Steinmann et al. 2009). The *hMLH1* (Puri et al. 2005), *RAR β* (Maruya et al. 2004), *p16*, and *MGMT* (Puri et al. 2005; Maruya et al. 2004) genes have also been found to be frequently methylated in HNSCC. The higher increased methylation of the TSG is usually associated with advanced tumor stages and undifferentiated HNSCC. This has been primarily shown for the *p16* and *RASSF5* genes (Steinmann et al. 2009). In the same study, *RASSF4* gene methylation was more frequent in patients with advanced tumor stage and recurrent HNSCC than patients without relapse. Higher methylation of the *p16*, *RAR β* , and *RASSF1* genes was also reported in a study in which matched normal samples were not available (Okami et al. 2005).

In a study investigating three TSG functioning in carcinogen metabolism (*CYP1A1*, *CYP2A13*, and *GSTM1*), the genes were found to be moderately (27.4–58.1%) methylated in the tumors, while methylation levels in normal tissue were much lower. A significant correlation was reported between smoking and the methylation status of the *CYP1A1* and *CYP2A13* genes (Sharma et al. 2010).

Hypermethylation of the *hMLH1* gene, which plays an important role in DNA mismatch repair, has been found to be significantly associated with decreased *hMLH1* protein expression, MSI, and decreased cause-specific survival for HNSCC patients in various studies (Zuo et al. 2009; Demokan et al. 2006; Sengupta et al. 2007; Liu et al. 2003a, b, 2002). Methylation of both *hMLH1* and *hMSH2*

Table 2 Candidate genes frequently methylated in HNC

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>APC</i>	Adenomatous polyposis coli	Tumor suppression	HNSCC (Chen et al. 2007), SGC (Durr et al. 2010; Lee et al. 2010), NPC (Loyo et al. 2011)	MS-MLPA (Chen et al. 2007) QMSP (Durr et al. 2010; Loyo et al. 2011), MSP (Lee et al. 2010)	(HG,St,H) (Lee et al. 2010)	T (Chen et al. 2007; Durr et al. 2010; Lee et al. 2008; Loyo et al. 2011), MN (Durr et al. 2010; Lee et al. 2010)	21–34
<i>BLU</i>	MYND-type containing 10	Tumor suppression	NPC (Ayadi et al. 2008; Liu et al. 2003b; Loyo et al. 2011; Qiu et al. 2004)	QMSP (Loyo et al. 2011), MSP (Ayadi et al. 2008; Liu et al. 2003b; Qiu et al. 2004)	H (Ayadi et al. 2008)	T (Ayadi et al. 2008; Liu et al. 2003b; Loyo et al. 2011; Qiu et al. 2004, NE (Liu et al. 2003b; Qiu et al. 2004)	34–74
<i>CCNA1</i>	Cyclin A1	Cell cycle	OSCC (Shaw et al. 2006) HNC (Tan et al. 2008; Tokumaru et al. 2004), NPC (Yanatsanejeit et al. 2008)	PS (Shaw et al. 2006), BS (Tokumaru et al. 2004), QMSP (Tan et al. 2008) MSP (Yanatsanejeit et al. 2008), COBRA (Yanatsanejeit et al. 2008)	HG (Shaw et al. 2006)	T (Shaw et al. 2006; Tan et al. 2008; Tokumaru et al. 2004; Yanatsanejeit et al. 2008), NE (Tokumaru et al. 2008; Yanatsanejeit et al. 2008) MN (Shaw et al. 2006), SM (Tan et al. 2008), L (Yanatsanejeit et al. 2008)	45–53
<i>CDH1</i>	E-cadherin	Cell adhesion	HNSCC (De Schutter et al. 2009; Hasegawa et al. 2002; Righini et al. 2007; Steinmann et al. 2009), HPC (Dikshit et al. 2007) SGC (Zhang et al. 2007a), OSCC (Chang et al. 2002; De Moraes et al. 2008; Maeda et al. 2007a; Viswanathan et al. 2003; Yeh et al. 2002) LC (Azarschab et al. 2003; Dikshit et al. 2007) NPC (Ayadi et al. 2008; Chang et al. 2003b; Kao et al. 2002; Krishna et al. 2005;	MSP (Ayadi et al. 2008; Azarschab et al. 2003; Chang et al. 2003b; Chang et al. 2002; De Moraes et al. 2008; De Schutter et al. 2009; Dikshit et al. 2007; Hasegawa et al. 2002; Krishna et al. 2005; Li et al. 2003a, b) MSP (Maeda et al. 2007a; Niemhom et al. 2008; Righini et al. 2007a) Steinmann et al. 2007; Yeh et al. 2002) NPC (Azarschab et al. 2003; Dikshit et al. 2007) NPC (Ayadi et al. 2008; Chang et al. 2003b; Kao et al. 2002; Krishna et al. 2005;	(B-LRC, B-S) (De Schutter et al. 2009) (B-DFS, B-DSS, B-O) (De Schutter et al. 2009), (TU,St,TS) (Hasegawa et al. 2002) MET (Azarschab et al. 2003; Li et al. 2003a), (PD,PI) (Zhang et al. 2007a) LNM (Ayadi et al. 2008; De Moraes et al. 2008; Li et al. 2003b), I (Li et al. 2003a) EBV (Kao et al. 2002;	M-SA (Hasegawa et al. 2002; Righini et al. 2007), NE (Chang et al. 2003b; Niemhom et al. 2008; Tsao et al. 2003) MN (Righini et al. 2007; Steinmann et al. 2009; Viswanathan et al. 2003; Yeh et al. 2002) SA-H (Righini et al. 2007) LN (Chang et al. 2002; Li et al. 2003a; Li et al. 2003b) T (Ayadi et al. 2008; Azarschab et al. 2003; Chang et al. 2002, 2003b;	23–85

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>CHFR</i>	Checkpoint with forkhead and ring finger domains	Early G2/M checkpoint	Li et al. 2003a, b; Niemhom et al. 2008; Tsao et al. 2003; Wong et al. 2003b)	Zhang et al. 2007a), SRM-PCR (Viswanathan et al. 2003) BS (Kao et al. 2002)	Krishna et al. 2005; Li et al. 2003a; Niemhom et al. 2008; Tsao et al. 2003) St (Niemhom et al. 2008)	De Moraes et al. 2008; De Schutter et al. 2009; Dikshit et al. 2007; Hasegawa et al. 2002; Kao et al. 2002; Krishna et al. 2005; Li et al. 2003a) T (Li et al. 2003b; Maeda et al. 2007a; Niemhom et al. 2008; Righini et al. 2007; Steinmann et al. 2009; Tsao et al. 2003; Viswanathan et al. 2003) T (Wong et al. 2003b; Yeh et al. 2002; Zhang et al. 2007a)	19–61
			HNSCC (Chen et al. 2007; Yalniz et al. 2011) OSCC (Baba et al. 2009; Toyota et al. 2003), NPC (Cheung et al. 2005)	MS-MLPA (Chen et al. 2007; Yalniz et al. 2011) MSP (Baba et al. 2009; Cheung et al. 2005), MSRE (Toyota et al. 2003)	n.a.	T (Baba et al. 2009; Chen et al. 2007; Cheung et al. 2005; Toyota et al. 2003; Yalniz et al. 2011), MN (Baba et al. 2009; Toyota et al. 2003) NE (Baba et al. 2003) NE (Baba et al. 2009; Cheung et al. 2005; Toyota et al. 2003)	
<i>DAPK1</i>	Death-associated protein kinase 1	Apoptosis	HNSCC (Chen et al. 2007; Hasegawa et al. 2002; Nayak et al. 2007; Righini et al. 2001; Sanchez-Cespedes et al. 2000; Steinmann et al. 2009) OSCC (Ogi et al. 2002), SGC (Li et al. 2005), LC (Zhang and Kong 2004)	MS-MLPA (Chen et al. 2007) QMSP (Nayak et al. 2007), MSRE (Ogi et al. 2002) MSP (Calmon et al. 2007; Chang et al. 2003b; Dikshit et al. 2007; Fendri et al. 2009; Hasegawa et al. 2002; Kong et al. 2006; Kwong et al. 2002; Li et al. 2005) MSP (Righini et al. 2007; Rosas et al. 2001; Sanchez-Cespedes et al. 2000; Steinmann et al. 2009; Kong et al. 2006; Kwong et al. 2002; Zhang and Kong 2004),	(St,TS,TU) (Hasegawa et al. 2002) LNM (Calmon et al. 2007; Fendri et al. 2009; Hasegawa et al. 2002; Sanchez-Cespedes et al. 2000) St (Sanchez-Cespedes et al. 2000)	M-SA (Chang et al. 2003b; Hasegawa et al. 2002; Righini et al. 2007; Rosas et al. 2001) NE (Chang et al. 2003b; Kwong et al. 2002; Wong et al. 2002), M-SE (Sanchez-Cespedes et al. 2000) SA-H (Righini et al. 2007), CINT (Kong et al. 2006) MN (Fendri et al. 2009; Righini et al. 2007; Steinmann et al. 2009; Zhang and Kong 2004), (L) (Wong et al. 2002) T (Calmon et al. 2007; Chang et al. 2003b;	7–77

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>DCC</i>	Deleted in colorectal cancer	Tumor suppression	OSCC (Kaur et al. 2010; Ogi et al. 2002), HNSCC (Carvalho et al. 2006; Tan et al. 2008), NPC (Loyo et al. 2011)	QMSP (Carvalho et al. 2006; Kaur et al. 2010; Loyo et al. 2011; Ogi et al. 2008), BS (Ogi et al. 2002)	(I, P-S) (Ogi et al. 2002)	Chen et al. 2007; Dikshit et al. 2007; Fendri et al. 2009; Hasegawa et al. 2002; Kong et al. 2006; Kwong et al. 2002; Li et al. 2005; Nayak et al. 2007; Ogi et al. 2002; T (Righini et al. 2007; Rosas et al. 2001; Sanchez-Céspedes et al. 2000; Steinmann et al. 2009; Wong et al. 2002; Zhang and Kong 2004)	50–75
<i>DLC1</i>	Deleted in liver cancer 1	Tumor suppression	NPC (Loyo et al. 2011; Seng et al. 2007)	QMSP (Loyo et al. 2011; Seng et al. 2007)	n.a.	T (Loyo et al. 2011; Seng et al. 2007), (MN, NE, SM) (Seng et al. 2007)	43–89
<i>DLEC1</i>	Deleted in lung and esophageal cancer	Tumor suppression	NPC (Ayadi et al. 2008; Loyo et al. 2011)	QMSP (Loyo et al. 2011), MSP (Ayadi et al. 2008)	H (Ayadi et al. 2008)	T (Ayadi et al. 2008; Loyo et al. 2011)	60–86
<i>EDNRB</i>	Endothelin receptor type B	Signaling mechanism	HNSCC (Demokan et al. 2010), OSCC (Kaur et al. 2010; Pattani et al. 2010), PM-OCL (Pattani et al. 2010), NPC (Lo et al. 2002; Zhou et al. 2007)	QMSP (Demokan et al. 2010; Kaur et al. 2010; Pattani et al. 2010), MSP (Lo et al. 2002; Zhou et al. 2007)	H (Pattani et al. 2010)	T (Demokan et al. 2010; Kaur et al. 2010; Lo et al. 2002; Pattani et al. 2010; Zhou et al. 2007) SA-H (Demokan et al. 2010; Kaur et al. 2010; Pattani et al. 2010), SE-H (Kaur et al. 2010) NE (Kaur et al. 2010; Lo et al. 2002)	60–97

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>HIN-1</i>	High-in-normal 1	Tumor suppression	OSCC (Huang et al. 2009), NPC (Wong et al. 2003a)	PCR-DHPLC (Huang et al. 2009), MSP (Wong et al. 2003a)	P-DFS (Huang et al. 2009)	T (Huang et al. 2009; Wong et al. 2003a), (NE, SA-H, L) (Wong et al. 2003a)	7.3–77
<i>hMLH1</i>	mutL homolog 1	DNA repair	HNSCC (Demokan et al. 2006; Liu et al. 2002; Liu et al. 2003a; Puri et al. 2005; Sengupta et al. 2007; Steinmann et al. 2009; Zuo et al. 2009) PM-OCL (Sengupta et al. 2007) OSCC (Czerninski et al. 2009), NPC (Tan et al. 2006; Wong et al. 2003b)	MSP (Czerninski et al. 2009; Liu et al. 2003a; Puri et al. 2005; Steinmann et al. 2009; Tan et al. 2006) MSP (Wong et al. 2003b; Zuo et al. 2009), MSRE (Demokan et al. 2006; Liu et al. 2003a; Sengupta et al. 2007)	H-MSI (Demokan et al. 2006; Sengupta et al. 2007; Zuo et al. 2009) P-S (Zuo et al. 2009)	MN (Sengupta et al. 2007; Steinmann et al. 2009), NE (Czerninski et al. 2009), T (Czerninski et al. 2009; Demokan et al. 2006; Liu et al. 2002, 2003a) T (Puri et al. 2005; Sengupta et al. 2007; Steinmann et al. 2009; Tan et al. 2006; Wong et al. 2003b; Zuo et al. 2009)	32.5–50
<i>hMSH2</i>	mutS homolog 2	DNA repair	HNSCC (Demokan et al. 2006; Sengupta et al. 2007), PM-OCL (Sengupta et al. 2007) OSCC (Czerninski et al. 2009)	MSP (Czerninski et al. 2009), MSRE (Demokan et al. 2006; Sengupta et al. 2007)	n.a.	MN (Sengupta et al. 2007), T (Czerninski et al. 2009; Demokan et al. 2010; Sengupta et al. 2007), NE (Czerninski et al. 2009)	30–50
<i>KIF1A</i>	Kinesin family member 1A	Axonal transport of synaptic vesicles and cell division	HNSCC (Demokan et al. 2010; Hoque et al. 2008), OSCC (Kaur et al. 2010; Pattani et al. 2010), PM-OCL (Pattani et al. 2010), NPC (Loyo et al. 2011)	QMSP (Demokan et al. 2010; Hoque et al. 2008; Kaur et al. 2010; Loyo et al. 2011; Pattani et al. 2010)	ANS (Demokan et al. 2010), H (Pattani et al. 2010)	T (Demokan et al. 2010; Hoque et al. 2008; Kaur et al. 2010; Loyo et al. 2011; Pattani et al. 2010) SA-H (Demokan et al. 2010; Kaur et al. 2010; Pattani et al. 2010), SE-H (Kaur et al. 2010) NE (Hoque et al. 2008; Kaur et al. 2010)	35–98
<i>MGMT</i>	O(6)-methylguanine-DNA methyltransferase	DNA repair	HNSCC (De Schutter et al. 2009; Hasegawa et al. 2002; Manuya et al. 2004; Puri et al. 2005; Righini et al. 2007; Rosas et al. 2001) HNSCC (Sanchez-Cespedes et al. 2000;	MSP (De Schutter et al. 2009; Dikshit et al. 2007; Hasegawa et al. 2002; Kato et al. 2006; Manuya et al. 2004; Puri et al. 2005) MSP (Righini et al. 2007;	(St, TS, TU) (Hasegawa et al. 2002), AU (Puri et al. 2005) (P-S, P-DFS) (Tàiooli et al. 2009) (I-RC, P-P) (Zuo et al. 2004)	M-SA (Hasegawa et al. 2002; Righini et al. 2007; Rosas et al. 2001), M-SE (Sanchez-Cespedes et al. 2000) SA-H (Righini et al. 2007)	6–56

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
			Steinmann et al. 2009; Zuo et al. 2004) OSCC (Dikshit et al. 2007; Kato et al. 2006; Taioli et al. 2009; Viswanathan et al. 2003) PM-HNL (Maruya et al. 2004), LC (Zhang et al. 2004, 2006) SRM-PCR (Viswanathan et al. 2003) PC (Dikshit et al. 2007; Taioli et al. 2009), NPC (Wong et al. 2003b)	Rosas et al. 2001; Sanchez-Cespedes et al. 2000; Steinmann et al. 2009; Taioli et al. 2009) MSP (Wong et al. 2003b; Zhang et al. 2004, 2006; Zuo et al. 2004) SRM-PCR (Viswanathan et al. 2003)		MN (Kato et al. 2006; Maruya et al. 2004; Righini et al. 2007; Steinmann et al. 2009; Viswanathan et al. 2003; Zhang et al. 2004, 2006) NE (Zhang et al. 2004, 2006) T (De Schutter et al. 2009; Dikshit et al. 2007; Hasegawa et al. 2002; Kato et al. 2006; Maruya et al. 2004; Puri et al. 2005; Righini et al. 2007; Rosas et al. 2001) T (Sanchez-Cespedes et al. 2000; Steinmann et al. 2009; Taioli et al. 2009; Viswanathan et al. 2003; Wong et al. 2003b; Zhang et al. 2004, 2006; Zuo et al. 2004)	
<i>MIN1</i>	Methylated in tumor-1	Synaptic vesicle exocytosis	OSCC (Ogi et al. 2002), SGC (Durr et al. 2010)	MSRE (Ogi et al. 2002), QMSP (Durr et al. 2010)	(ANS, P-P) (Ogi et al. 2002)	T (Durr et al. 2010; Ogi et al. 2002), MN (Durr et al. 2010)	23–48
<i>MIN31</i>	Methylated in tumor-31	Tumor suppression	OSCC (Ogi et al. 2002), HNSCC (Carvalho et al. 2008)	MSRE (Ogi et al. 2002), QMSP (Carvalho et al. 2008)	(St, P-P) (Ogi et al. 2002)	T (Carvalho et al. 2008; Ogi et al. 2002), NE (Carvalho et al. 2008)	15–64
<i>p14</i>	Alternative open reading frame (ARF) of INK4a locus	Tumor suppression	OSCC (Ishida et al. 2005; Kordi-Tamandani et al. 2010; Ogi et al. 2002; Sailasree et al. 2008; Shintani et al. 2001) HNSCC (Weber et al. 2002), PM-OCL (Takeshima et al. 2008) SGC (Nishimine et al. 2003)	MSRE (Ogi et al. 2002) MSP (Ishida et al. 2005; Kordi-Tamandani et al. 2010; Nishimine et al. 2003; Sailasree et al. 2008; Shintani et al. 2001; Takeshima et al. 2008; Weber et al. 2002)	G-P (Ogi et al. 2002; Sailasree et al. 2008), R-RC (Sailasree et al. 2008) (LNM, TS, St) (Ishida et al. 2005)	T (Ishida et al. 2005; Kordi-Tamandani et al. 2010; Nishimine et al. 2003; Ogi et al. 2002; Sailasree et al. 2008; Shintani et al. 2001; Takeshima et al. 2008; Weber et al. 2002) NE (Kordi-Tamandani et al. 2010; Takeshima et al. 2008)	14–34

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>p15</i>	Cyclin-dependent kinase inhibitor 2B	Tumor suppression	OSCC (Ogi et al. 2002; Shintani et al. 2001; Viswanathan et al. 2003; Yeh et al. 2002), HNC (Chang et al. 2004)	SRM-PCR (Viswanathan et al. 2003), MSRE (Ogi et al. 2002) QMSP (Chang et al. 2004) MSP (Chang et al. 2003b; Shintani et al. 2001; Takeshima et al. 2008; Wong et al. 2003b; Yeh et al. 2003)	ANS (Ogi et al. 2002), (TU, AU) (Chang et al. 2004)	MN (Viswanathan et al. 2003), M-SA (Chang et al. 2003b; Chang et al. 2004; Takeshima et al. 2008) NE (Chang et al. 2003b; Takeshima et al. 2008) T (Chang et al. 2003b; Chang et al. 2004; Ogi et al. 2002; Shintani et al. 2001; Takeshima et al. 2008; Viswanathan et al. 2003; Wong et al. 2003b; Yeh et al. 2003)	22–65
			PM-OCL (Takeshima et al. 2008), NPC (Chang et al. 2003b; Wong et al. 2003b)				
<i>p16</i>	Cyclin-dependent kinase inhibitor 2A (CDKN2A)	Tumor suppression	OSCC (El-Naggar et al. 1997; González et al. 1997; Haill et al. 2008; Huang et al. 2002; Ishida et al. 2005; Kato et al. 2006; Kaur et al. 2010; Miracca et al. 1999; Nakahara et al. 2006) OSCC (Nakahara et al. 2001; Ogi et al. 2002; Ohta et al. 2009; Reed et al. 1996; Riese et al. 1999; Ruesga et al. 2007; Sailasree et al. 2008) OSCC (Shaw et al. 2006; Shintani et al. 2001; Sinha et al. 2009; Tao et al. 1997; Viswanathan et al. 2003; Yakushiji et al. 2001; Yeh et al. 2003) HNSCC (Ai et al. 2003; Carvalho et al. 2008; Hasegawa et al. 2002; Koscielny et al. 2007; Maruya et al. 2004; Okami et al. 2005; Puri et al. 2005) HNSCC (Righini et al. 2007; Rosas et al. 2001; Sanchez-Cespedes	QMSP (Carvalho et al. 2008; Kaur et al. 2010; Tan et al. 2008) SRM-PCR (Viswanathan et al. 2003), PS (Hall et al. 2008; Shaw et al. 2006) SB (Reed et al. 1996), MSRE (El-Naggar et al. 1997; González et al. 1999; Ogi et al. 2002; Tao et al. 1997) MSP (Agnese et al. 2006; Ai et al. 2003; Cao et al. 2009; Chang et al. 2003b; Dikshit et al. 2007; Hasegawa et al. 2002; Huang et al. 2002; Ishida et al. 2005; Kato et al. 2006; Kresty et al. 2002) MSP (Kwong et al. 2002; Li 1996; Maruya et al. 2004; Nakahara et al. 2006; Nakahara et al. 2001; Nishimine et al.	(A-TU,TU) (Hasegawa et al. 2002) (St, LNM, TS) (Hasegawa et al. 2002; Ishida et al. 2005) ANS (Kresty et al. 2002), PD (Steinmann et al. 2009) (I-RC, P-P) (Sailasree et al. 2008)	T (Agnese et al. 2006; Ai et al. 2003; Cao et al. 2009; Carvalho et al. 2008; Chang et al. 2003b; Dikshit et al. 2007; El-Naggar et al. 1997; González et al. 1999; Guo et al. 2007; Ha and Califano 2003; Hall et al. 2008; Hasegawa et al. 2002; Huang et al. 2002; Ishida et al. 2005) T (Kato et al. 2006; Kaur et al. 2010; Koscielny et al. 2007; Kresty et al. 2002; Kwong et al. 2002; Li et al. 2005; Lo et al. 1996; Maruya et al. 2004; Miracca et al. 1999; Nakahara et al. 2006) T (Nakahara et al. 2001; Nishimine et al. 2003; Ogi et al. 2002; Ohta et al. 2009; Okami et al. 2005; Puri et al. 2005; Reed et al.	5–68

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
			et al. 2000; Steinmann et al. 2009) PM-HNL (Cao et al. 2009; Hall et al. 2008; Kresty et al. 2002; Maruya et al. 2004; Takeshima et al. 2008), SGC (Agnese et al. 2006; Guo et al. 2007; Li et al. 2002; Nishimine et al. 2003), LC (Agnese et al. 2006; Dikshit et al. 2007; Smigiell et al. 2004) HPC (Dikshit et al. 2007), NPC (Chang et al. 2003b; Kwong et al. 2002; Lo et al. 1996; Tan et al. 2006; Wong et al. 2003b)	2003) MSP (Ohta et al. 2009; Okami et al. 2005; Puri et al. 2005; Riese et al. 1999; Righini et al. 2007; Rosas et al. 2001; Rubin 2011; Ruesga et al. 2007; Sallastree et al. 2008; Sanchez-Céspedes et al. 2000; Shaw et al. 2006; Shintani et al. 2001; Sinha et al. 2009; Smigiell et al. 2004; Steinmann et al. 2009) T (Takeshima et al. 2008; Tan et al. 2006, 2008; Tao et al. 1997; Viswanathan et al. 2003; Weber et al. 2002; Wong et al. 2003b; Yakushiji et al. 2001; Yeh et al. 2003) SA-H (Carvalho et al. 2008; Kaur et al. 2010; Righini et al. 2007) SE-H (Kaur et al. 2010), SM (Sinha et al. 2009; Tan et al. 2008) M-SA (Carvalho et al. 2008; Hasegawa et al. 2002; Righini et al. 2007; Rosas et al. 2001) NE (Carvalho et al. 2008; Chang et al. 2003b; Guo et al. 2007; Kaur et al. 2010; Kwong et al. 2002; Lo et al. 1996; Takeshima et al. 2008) M-SE (Carvalho et al. 2008; Nakahara et al. 2006; Sanchez-Céspedes et al. 2000) MN (Huang et al. 2002; Kato et al. 2006; Kresty et al. 2002)	2003) MSP (Ohta et al. 2009; Okami et al. 2005; Puri et al. 2005; Riese et al. 1999; Righini et al. 2007; Rosas et al. 2001; Rubin 2011; Ruesga et al. 2007; Sallastree et al. 2008; Sanchez-Céspedes et al. 2000; Shaw et al. 2006; Shintani et al. 2001; Sinha et al. 2009; Smigiell et al. 2004; Steinmann et al. 2009) T (Takeshima et al. 2008; Tan et al. 2006, 2008; Tao et al. 1997; Viswanathan et al. 2003; Weber et al. 2002; Wong et al. 2003b; Yakushiji et al. 2001; Yeh et al. 2003) SA-H (Carvalho et al. 2008; Kaur et al. 2010; Righini et al. 2007) SE-H (Kaur et al. 2010), SM (Sinha et al. 2009; Tan et al. 2008) M-SA (Carvalho et al. 2008; Hasegawa et al. 2002; Righini et al. 2007; Rosas et al. 2001) NE (Carvalho et al. 2008; Chang et al. 2003b; Guo et al. 2007; Kaur et al. 2010; Kwong et al. 2002; Lo et al. 1996; Takeshima et al. 2008) M-SE (Carvalho et al. 2008; Nakahara et al. 2006; Sanchez-Céspedes et al. 2000) MN (Huang et al. 2002; Kato et al. 2006; Kresty et al. 2002)	1996) T (Riese et al. 1999; Righini et al. 2007; Rosas et al. 2001; Rubin 2011; Ruesga et al. 2007; Sallastree et al. 2008; Sanchez-Céspedes et al. 2000; Shaw et al. 2006; Shintani et al. 2001; Sinha et al. 2009; Smigiell et al. 2004; Steinmann et al. 2009) T (Takeshima et al. 2008; Tan et al. 2006, 2008; Tao et al. 1997; Viswanathan et al. 2003; Weber et al. 2002; Wong et al. 2003b; Yakushiji et al. 2001; Yeh et al. 2003) SA-H (Carvalho et al. 2008; Kaur et al. 2010; Righini et al. 2007) SE-H (Kaur et al. 2010), SM (Sinha et al. 2009; Tan et al. 2008) M-SA (Carvalho et al. 2008; Hasegawa et al. 2002; Righini et al. 2007; Rosas et al. 2001) NE (Carvalho et al. 2008; Chang et al. 2003b; Guo et al. 2007; Kaur et al. 2010; Kwong et al. 2002; Lo et al. 1996; Takeshima et al. 2008) M-SE (Carvalho et al. 2008; Nakahara et al. 2006; Sanchez-Céspedes et al. 2000) MN (Huang et al. 2002; Kato et al. 2006; Kresty et al. 2002)	1996) T (Riese et al. 1999; Righini et al. 2007; Rosas et al. 2001; Rubin 2011; Ruesga et al. 2007; Sallastree et al. 2008; Sanchez-Céspedes et al. 2000; Shaw et al. 2006; Shintani et al. 2001; Sinha et al. 2009; Smigiell et al. 2004; Steinmann et al. 2009) T (Takeshima et al. 2008; Tan et al. 2006, 2008; Tao et al. 1997; Viswanathan et al. 2003; Weber et al. 2002; Wong et al. 2003b; Yakushiji et al. 2001; Yeh et al. 2003) SA-H (Carvalho et al. 2008; Kaur et al. 2010; Righini et al. 2007) SE-H (Kaur et al. 2010), SM (Sinha et al. 2009; Tan et al. 2008) M-SA (Carvalho et al. 2008; Hasegawa et al. 2002; Righini et al. 2007; Rosas et al. 2001) NE (Carvalho et al. 2008; Chang et al. 2003b; Guo et al. 2007; Kaur et al. 2010; Kwong et al. 2002; Lo et al. 1996; Takeshima et al. 2008) M-SE (Carvalho et al. 2008; Nakahara et al. 2006; Sanchez-Céspedes et al. 2000) MN (Huang et al. 2002; Kato et al. 2006; Kresty et al. 2002)

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>PGP9.5 (UCHL1)</i>	Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)	Processing of ubiquitin precursors and of ubiquitinated proteins	SGC (Durr et al. 2010), HNC (Tokumaru et al. 2004, 2008) OSCC (Tokumaru et al. 2008), NPC (Li et al. 2010; Loyo et al. 2011)	BS (Tokumaru et al. 2004), MSP (Li et al. 2010) QMSP (Durr et al. 2010; Loyo et al. 2011; Tokumaru et al. 2008)	n.a.	MN (Mariuya et al. 2004; Miracca et al. 1999; Riese et al. 1999; Righini et al. 2007; Shaw et al. 2006; Steinmann et al. 2009; Viswanathan et al. 2003) T (Durr et al. 2010; Li et al. 2010; Loyo et al. 2011; Tokumaru et al. 2004, 2008) MN (Durr et al. 2010), NE (Tokumaru et al. 2004)	60–82
<i>RARB</i>	Retinoic acid receptor beta	Tumor suppression	HNSCC (Chen et al. 2007; Mariuya et al. 2004; Okami et al. 2005; Steinmann et al. 2009; Yalniz et al. 2011; Youssef et al. 2004) PM-HNL (Mariuya et al. 2004), PM-OCL (Youssef et al. 2004) SGC (Durr et al. 2010), NPC (Fendri et al. 2009; Kwong et al. 2005b)	MS-MLPA (Chen et al. 2007; Yalniz et al. 2011) MSP (Fendri et al. 2009; Kwong et al. 2005b; Kwong et al. 2002; Mariuya et al. 2004; Okami et al. 2005) MSP (Steinmann et al. 2009; Youssef et al. 2004), QMSP (Durr et al. 2010)	(St, H) (Fendri et al. 2009)	MN (Durr et al. 2010; Fendri et al. 2009; Mariuya et al. 2004; Steinmann et al. 2009) NE (Kwong et al. 2002; Youssef et al. 2004) T (Chen et al. 2004) T (Chen et al. 2007; Durr et al. 2010; Fendri et al. 2009; Kwong et al. 2002, 2005b; Mariuya et al. 2004; Okami et al. 2005; Steinmann et al. 2009; Yalniz et al. 2011; Youssef et al. 2004)	15–80
<i>RASSF1A</i>	Ras association (RalGDS/AF-6) domain family member 1A	Tumor suppression	HNSCC (Carvalho et al. 2008; Chen et al. 2007; Dong et al. 2003; Hasegawa et al. 2002; Okami et al. 2005; Righini et al. 2007; Steinmann et al. 2009), OSCC (Huang et al. 2009), SGC (Li et al. 2009), NPC (Chang et al. 2003b; Fendri et al. 2009; Kwong et al. 2002; Lo et al. 2001;	MS-MLPA (Chen et al. 2007), QMSP (Carvalho et al. 2008) PCR-DHPLC (Huang et al. 2009) MSP (Chang et al. 2003b; Dong et al. 2003; Fendri et al. 2009; Hasegawa et al. 2002; Kwong et al. 2002; Li et al. 2005) MSP (Lo et al. 2001; Okami et al. 2005) NPC (Chang et al. 2003b; Fendri et al. 2009; Kwong et al. 2002; Lo et al. 2001;	HPV (Dong et al. 2003) (St,TS,TU) (Hasegawa et al. 2002) (P-DFS) (Huang et al. 2009) (HG,St,MET) (Li et al. 2005) (LNM, A) (Fendri et al. 2009), EBV (Zhou et al. 2005)	M-SA (Chang et al. 2003b; Hasegawa et al. 2002; Righini et al. 2007) MN (Righini et al. 2007; Steinmann et al. 2009; Zhou et al. 2005), SA-H (Righini et al. 2007) NE (Carvalho et al. 2008; Chang et al. 2003b; Dong et al. 2003; Fendri et al. 2009; Kwong et al. 2005b; Lo et al. 2001; Qiu et al. 2004; Wang et al.	2.4–84

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>RASSF2</i>	Ras association (RalGDS/AF-6) domain family member 2	Tumor suppression	Qiu et al. 2004; Tan et al. 2006; Wang et al. 2009; Wong et al. 2003b; Zhou et al. 2005)	MSP (Tan et al. 2006; Wang et al. 2009; Wong et al. 2003b; Zhou et al. 2005)		2009) T (Carvalho et al. 2008; Chang et al. 2003b; Chen et al. 2007; Dong et al. 2003; Fendri et al. 2009; Hasegawa et al. 2002; Huang et al. 2009; Kwong et al. 2002; Li et al. 2005; Lo et al. 2001) T (Okami et al. 2005; Qiu et al. 2004; Righini et al. 2007; Steinmann et al. 2009; Tan et al. 2006; Wang et al. 2009; Wong et al. 2003b; Zhou et al. 2005)	22–51
<i>SFRP1</i>	Secreted protein 1	Inhibition of Wnt signaling	HNSCC (Steinmann et al. 2009) OSCC (Huang et al. 2009; Imai et al. 2008), NPC (Zhang et al. 2007b)	COBRA (Imai et al. 2008; Steinmann et al. 2009) PCR-DHPLC (Huang et al. 2009), MSP (Zhang et al. 2007b)	P-DFS (Huang et al. 2009), LNM (Zhang et al. 2007b)	T (Huang et al. 2009; Imai et al. 2008; Steinmann et al. 2009; Zhang et al. 2007b), MN (Imai et al. 2008; Steinmann et al. 2009) NE (Zhang et al. 2007b) (T, MN) (Lee et al. 2010; Sogabe et al. 2008)	24–58.6
<i>TIG1</i>	Tazarotene-induced gene-1	Response to retinoic acid receptor	SGC (Lee et al. 2010), OSCC (Sogabe et al. 2008) HNSCC (Tokumaru et al. 2005), NPC (Kwong et al. 2005a; Yanatatsaneejit et al. 2008)	MSP (Lee et al. 2010; Sogabe et al. 2008) MSP (Kwong et al. 2005a; Tokumaru et al. 2005) MSP-COBRA (Yanatatsaneejit et al. 2008)	(HG, StH) (Lee et al. 2010), G (Sogabe et al. 2008) n.a.	T (Kwong et al. 2005a; Tokumaru et al. 2005; Yanatatsaneejit et al. 2008), NE (Kwong et al. 2005a; Tokumaru et al. 2005; Yanatatsaneejit et al. 2008) L (Yanatatsaneejit et al. 2008)	51–91
<i>TIMP3</i>	Tissue inhibitor of metalloproteinases 3	Inhibition of angiogenesis and tumor growth	HNSCC (De Schutter et al. 2009; Nayak et al. 2007; Righini et al. 2007), SGC (Durr et al. 2010)	MSP (De Schutter et al. 2009; Righini et al. 2007), QMSP (Durr et al. 2010; Nayak et al. 2007)	(B-LRC, B-S) (De Schutter et al. 2009) (B-DFS, B-DSS, B-O) (De Schutter et al. 2009)	T (De Schutter et al. 2009; Durr et al. 2010; Nayak et al. 2007; Righini et al. 2007), MN (Durr et al. 2010; Righini et al. 2007)	40.5–71.8

Table 2 (continued)

Gene	Gene name	Gene function	Tumor type ^a	Method ^b	Clinical association ^c	Samples ^d	Methylation range (%)
<i>WIF1</i>	Wnt inhibitory factor 1	Inhibition of Wnt signaling	NPC (Chan et al. 2007; Fendri et al. 2010)	MSP (Chan et al. 2007; Fendri et al. 2010)	(TS, LNM) (Chan et al. 2007; Fendri et al. 2010) (MET, A) (Chan et al. 2007; Fendri et al. 2010)	M-SA (Righini et al. 2007), SA-H (Righini et al. 2007) (T, NE) (Chan et al. 2007; Fendri et al. 2010)	85–89.7
<i>I4-3-3 sigma</i>	Stratifin	Signaling mechanism	SGC (Gasco et al. 2002; Uchida et al. 2004), OSCC (Gasco et al. 2002) PM-OCL (Gasco et al. 2002), NPC (Yi et al. 2009)	MSP (Gasco et al. 2002; Uchida et al. 2004; Yi et al. 2009)	H (Uchida et al. 2004) (LNM, MET, S) (Yi et al. 2009)	T (Gasco et al. 2002; Uchida et al. 2004; Yi et al. 2009), MN (Gasco et al. 2002; Yi et al. 2009)	35–84

^aTumor types: OSCC oral squamous cell carcinoma, PM-OCL premalignant oral cavity lesions, PM-HNL premalignant head and neck lesions, SGC salivary gland carcinomas, LC larynx cancer, HPC hypopharyngeal cancer, PC pharyngeal cancer, NPC nasopharyngeal carcinoma

^bMethods: PCR polymerase chain reaction, MSP methylation-specific PCR, QMSP quantitative methylation-specific PCR, QRT-PCR quantitative reverse transcriptase PCR, MSRE methylation-specific restriction enzyme analysis, SRM-PCR sensitive restriction-multiplex PCR, MS-MLPA methylation-specific multiplex ligation-dependent probe amplification, COBRA combined bisulfite restriction analysis, PS pyrosequencing, SB Southern blot, BS bisulfite sequencing, PCR-DHPLC PCR-denaturing high-performance liquid chromatography

^cClinical: B-LRC better local recurrence, B/P-S better/poor survival, B/P-DFS better/poor disease-free survival, B/P-DSS better/poor disease-specific survival, B/P-O better/poor outcome, ANS anatomic site, I invasion, A-S age of smoking, St stage, LNM lymph node metastasis, TS tumor size, TU tobacco usage, I/R-RC increased/reduced recurrence, P/G-P poor/good prognosis, AU alcohol usage, H histology, HG high grade, MET distant metastasis, H-MSI high microsatellite instability, PD poor differentiation, PI perineural invasion, G gender, A age

^dSamples: T tumor, MN matched normal tissue, NE normal epithelium, M-SA matched salivary rinse, M-SE matched serum, SA-H salivary rinses from healthy people, SM surgical margin, SE-H serum from healthy people, LN lymph node, L lymphocytes, CINT chronic inflammatory nasopharyngeal tissues

genes may have an important role in oral carcinogenesis and have been associated with the susceptibility for oral malignancies (Czerninski et al. 2009).

Biomarkers predicting clinical response, tumor recurrence, or patient survival are not available for many cancer types, particularly for oral and pharyngeal cancer. Taioli et al. (2009) have studied the methylation of a panel of TSG in order to identify a possible correlation with survival and recurrence rates in patients with oral or pharyngeal cancer. *MGMT* promoter methylation was inversely associated with poor OS and DFS, indicating that *MGMT* promoter methylation may act as a possible prognostic biomarker for oral and pharyngeal cancer (Taioli et al. 2009). In oral epithelial dysplasia that transforms to OSCC, *p16* methylation may act as a candidate biomarker of malignant transformation, whereas methylation of the *MGMT*, *CYGB*, and *CCNA1* genes are not associated with malignancy (Hall et al. 2008). In oral carcinomas, methylation of the *p16* and *MGMT* genes are frequently observed as an early event (Kato et al. 2006). Promoter hypermethylation of the *p16*, *p15*, *hMLH1*, *MGMT*, and *CDHI* genes has been reported in OSCC (Viswanathan et al. 2003). The *Ras/PI3K/AKT* pathway is a major mechanism associated with radioresistance in OSCC. A study investigating four genes (*RASSF1A*, *RASSF2A*, *PTEN*, and *HIN-1*) in this pathway revealed that *RASSF1A* and *RASSF2A* methylation were more frequent in the tumors and significantly associated with poor DFS (Huang et al. 2009). Methylation of *CCNA1*, *CYGB*, and *p16* genes has also been correlated with the clinicopathological parameters in oral cancer (Shaw et al. 2006). In OSCC, different levels of methylation have been reported for the *p16*, *p15*, *p14*, *DCC*, *DAPK*, *MINT1*, *MINT2*, *MINT27*, and *MINT31* gene promoters and *DCC* methylation was associated with bone invasion of gingival tumors, invasiveness, and reduced survival (Ogi et al. 2002). Aberrant methylation of the *p14*, *p15*, and *p16* gene promoters has been reported in HNSCC (Weber et al. 2002), oral precancerous lesions (Takeshima et al. 2008), oral carcinomas (Sailasree et al. 2008; Yeh et al. 2003; Shintani et al. 2001), and salivary gland carcinomas (Nishimine et al. 2003). When normal tissue and benign and malignant salivary gland tumors were compared, significantly higher methylation of the *APC*, *RAR β* , *MINT1*, *PGP9.5*, and *TIMP3* genes were observed in salivary duct carcinoma (Durr et al. 2010). In adenoid cystic carcinomas of the salivary gland, *p16*, *RASSF1A*, and *DAPK* gene methylation is also a common event (Li et al. 2005).

In patients with laryngeal and hypopharyngeal cancers, promoter methylation of the *p16*, *MGMT*, *DAPK*, and *CDHI* genes are observed frequently (Dikshit et al. 2007; Azarschab et al. 2003). For tumors in the oropharynx, a statistically significant association between hypermethylation of the *DAPK1* gene and risk of lymph node metastases

has been reported, and significant evidence indicate an association between hypermethylation of the *ADAM23* gene and advanced tumor stage in larynx cancer (Calmon et al. 2007).

In a study investigating the methylation status of candidate TSG in surgical margins as a predictor of local recurrence in HNSCC, it has been shown that analysis of the *CDKN2A*, *CCNA1*, and *DCC* genes in the surgical margins by quantitative methylation-specific PCR (QMSP) can correctly predict local recurrences in HNSCC (Tan et al. 2008). Using candidate gene and discovery approaches, 21 genes were investigated in HNSCC and normal tissue samples. *p16*, *MINT31*, and *RASSF1A* gene methylation were detected only in HNSCC but not in the controls (Carvalho et al. 2008).

Data from mRNA expression array studies

Recently, studies investigating novel methylated TSG specific to the tumor types have made use of mRNA expression arrays to analyze more than 40,000 genetic regions on a single platform via pharmacological unmasking and discovery approaches (Yamashita et al. 2002; Tokumaru et al. 2004).

After bisulfite sequencing, rapid subtractive hybridization, and microarray analysis in order to determine genes that are induced to reexpression by the demethylating agent 5-aza-2'-deoxycytidine in HNSCC cell lines, 35 out of 78 genes were selected and only 3 of these (*CRABP2*, *MXI*, and *SLC15A3*) were verified by QMSP (Calmon et al. 2009). After methylation-specific PCR (MSP) analysis, *CRABP2* and *MXI* genes were highly methylated in primary HNSCC compared with lymphocytes from a healthy cohort. In addition, lack of the *CRABP2* protein was associated with poor survival rates, indicating that *CRABP2* expression may be a potential prognostic biomarker for patients with HNSCC.

In a study, *PGP9.5*, *CCNA1*, bone morphogenetic protein 2A (*BMP2A*), metallothionein 1G (*MT1G*), and neuromedin U (*NmU*) genes were highly methylated and *CCNA1* hypermethylation displayed an inverse correlation with *p53* mutations (Tokumaru et al. 2004).

Methylation of the Nischarin (*NISCH*), p21-activated protein kinase 3 (*PAK3*), *KIF1A*, and *OGDHL* genes has been reported in 8–52% of the patients with HNC, whereas no methylation was observed in the normal cohort (Hoque et al. 2008).

Global methylation

A recent study indicated the involvement of global DNA hypermethylation in the pathogenesis of HNSCC (Worsham

et al. 2010). Using DNA IP and Affymetrix whole-genome tiling arrays, 231 new and previously unreported genes out of 1,143 cancer genes on the array were identified via the whole-genome methylation approach.

In a study aiming to characterize early molecular changes in premalignant lesions of the oral cavity and the role of tobacco and alcohol consumption or HPV infections, the global methylation index was found to be 4.28 (95%CI, 4.1, 4.4) in the oral cancer case series. Methylation was inversely associated with tobacco use (Guerrero-Preston et al. 2009).

In cancer, abnormal demethylation leads to the loss of silencing in repetitive elements which are located on approximately 50% of the human genome, whereas in normal cells, these repetitive sequences are regulated by epigenetic silencing. DNA methylation alterations in HNC and adjacent nontumor tissues was investigated via a genome-wide microarray approach (Szpakowski et al. 2009). Of the more than 250,000 repetitive elements probed, between 5% and 8% displayed disease-related DNA methylation changes. Among the *SVA*, *HERV*, *LINE-1P*, *AluY* and *MaLR* families, *LINE-1* (Richards et al. 2009; Subbalekha et al. 2009; Smith et al. 2007), *SINE (Alu)* (Richards et al. 2009) repetitive elements, and *LRE1* (Furniss et al. 2008; Hsiung et al. 2007) showed loss of DNA methylation in the tumors when compared to matched normal adjacent tissue. *LINE* and *LRE1* hypomethylation were more frequently observed in HPV-negative than in HPV-positive tumors (Richards et al. 2009).

The Runt-related transcription factor 3 (*RUNX3*) gene plays a role in the transforming growth factor-beta ($TGF-\beta$)-induced tumor suppression pathway. Although *RUNX3* has been considered as a TSG in some studies (Bae et al. 1995; Li et al. 2002), it has been shown that the expression level of *RUNX3* in HNSCC tissues are higher than that in normal oral epithelial tissues due to demethylation (Ginos et al. 2004; Salto-Tellez et al. 2006). Therefore, it has been suggested that *RUNX3* may have an oncogenic role in HNSCC and its expression may predict malignant behavior and the effect of chemotherapeutic drugs in HNSCC as a potential biomarker (Tsunematsu et al. 2009). In contrast to HNSCC, the *RUNX3* gene is underexpressed in OSCC due to promoter hypermethylation, indicating that *RUNX3* plays an important role in oral carcinogenesis and may be a useful diagnostic marker and a potential therapeutic target for OSCC (Gao et al. 2009).

A recent report has shown that the *SEPT9*, *SLC5A8*, *FUSSEL18*, *EBF3*, and *IRX1* genes which act in the $TGF-\beta$ signaling pathway are commonly methylated and down-regulated in HNC (Bennett et al. 2009). In IP studies, all these candidate genes were observed to interact with the components of the $TGF-\beta$ pathway (Bennett et al. 2008). It was reported that decreased mitotic activity and increased

apoptosis rates were observed when the *SLC5A8*, *EBF3*, and *IRX1* genes are overexpressed.

Recently, HPV-infected HNSCC tumors have been shown to display higher levels of global DNA methylation. These tumors were universally methylated irrespective of the clinical factors and methylation of the *FUSSEL18*, *IRX1*, and *EBF3* genes were likely correlated with recurrences. Promoter methylation of the *FUSSEL18* and *SEPTIN9* genes was significantly associated with alcohol and tobacco consumption. A trend between HPV16 positivity and methylation of the *IRX1*, *EBF3*, *SLC5A8*, and *SEPT9* genes was noted and it has been suggested that this gene panel may be used for the selection of treatment modality (Bennett et al. 2010).

The Transketolase-like 1 (*TKTL1*) gene is a novel candidate oncogene, which is hypomethylated in human HNSCC tumor samples and contributes to HNSCC carcinogenesis via aerobic glycolysis and HIF1- α stabilization (Sun et al. 2010).

Studies of individual genes

Tumor suppressor genes

Significantly higher methylation of the *p14ARF* gene has been reported in OSCC compared to normal control tissues, implying that the methylation status of *p14ARF* may be an important determinant in the early diagnosis and treatment of OSCC (Kordi-Tamandani et al. 2010; Ishida et al. 2005).

Data on the methylation of the *p16* gene promoter is not consistent. The gene has been analyzed individually or in gene panels but with discordant results. In a study, *p16* methylation has been associated with malignant transformation of oral epithelial dysplasia and was considered a potential biomarker for the prediction of prognosis of mild or moderate oral epithelial dysplasia (Cao et al. 2009; Kresty et al. 2002). High methylation of the *p16* promoter region has also been reported in carcinomas of the tongue and methylation in the surgical margins were found to increase the risk of local recurrences 6.3-fold when compared with patients with negative margins (Sinha et al. 2009). Varying degrees of *p16* methylation has been reported in OSCC (Ohta et al. 2009; Ruesga et al. 2007; Nakahara et al. 2006; Huang et al. 2002; Yákuhiji et al. 2001; Nakahara et al. 2001; Miracca et al. 1999; Riese et al. 1999; El-Naggar et al. 1997; Tao et al. 1997; González et al. 1997; Reed et al. 1996), in mucoepidermoid carcinoma (MEC) of the salivary glands (Guo et al. 2007; Agnese et al. 2006), in HNC (Yalniz et al. 2011; Koscielny et al. 2007; Ai et al. 2003), and in larynx cancer (Smigiel et al. 2004). Conversely, there is also a report of low *p16* methylation in larynx cancer (Agnese et al. 2006).

DCC is a candidate TSG located on chromosome 18q21. Hypermethylation of *DCC* as a mechanism for inactivation

in HNSCC has been investigated (Carvalho et al. 2006). The *DCC* promoter was highly methylated in the tumors and there was a significant correlation between *DCC* promoter region hypermethylation and lack of *DCC* expression.

In a study investigating the methylation and expression levels of the *APC* and *SFRP* genes, both genes were highly methylated in MEC but not in adjacent normal tissue. There was significant correlation between methylation and low *SFRP1* expression. Methylation of the *SFRP1* gene was the main cause of decreased *SFRP1* expression. Beta-catenin expression was also associated with reduced *SFRP1* expression. In addition, both *SFRP1* and beta-catenin expression were associated with tumor grade and stage. Survival was particularly poor in patients with reduced *SFRP1* and cytoplasmic/nuclear beta-catenin expression. It has been suggested that detection of *SFRP1* expression and aberrant beta-catenin expression in the cell may be useful biomarkers of tumor progression and prognosis in patients with MEC (Lee et al. 2010).

Alterations in *TGF- β* signaling are common in HNSCC. Hypermethylation of *TGF- β* type I receptor (*TGFBR-1*) gene was evaluated via MSP and restriction enzyme-mediated PCR (MSRE). *TGFBR-1* expression was lost in 83% of the HNSCC tumors and was linked to DNA hypermethylation of the CpG-rich promoter region in 62% of the samples (Muñoz-Antonia et al. 2009).

NDRG2 is a candidate TSG involved in oral squamous cell cancers via the Akt signaling pathway. Reduced *NDRG2* mRNA levels, caused by promoter methylation, have been reported in most of the OSCC patients and in several cases of precancerous leukoplakia with dysplasia (Furuta et al. 2010).

Hypermethylation of the *FancB* gene has been observed in sporadic HNSCC tumors (Smith et al. 2010), while methylation of the *SYK* gene has been frequently observed in OSCC; the downregulation of *SYK* expression due to promoter methylation was associated with metastasis (Ogane et al. 2009). *MGMT* gene methylation is observed in laryngeal cancer (Zhang et al. 2006, 2004) and HNSCC (Zuo et al. 2004), but not in normal larynx tissue.

The *MALTI* gene, responsible for activating nuclear factor-kappaB in lymphocyte lineages, is located in a genomic region encoding putative TSG and is expressed in the nucleus of oral epithelial cells. Absence of expression due to epigenetic inactivation during tumor progression has been associated with tumor recurrence and poor patient survival, suggesting that analysis of *MALTI* expression may be a useful predictive and prognostic marker for OSCC (Chiba et al. 2009).

In primary OSCC, aberrant methylation of the *RASSF2* gene and a high frequency of *ROBO1* methyla-

tion have been reported in early dysplastic lesions of the head and neck (Imai et al. 2008; Ghosh et al. 2009). A significant inverse correlation between *RASSF1A* promoter methylation and HPV infection in HNSCC has been shown (Dong et al. 2003).

GALRI methylation is observed in primary HNSCC tumors and correlates with decreased *GALRI* expression, as well as increased tumor size, lymph node status, tumor stage, *CCND1* expression, *p16* methylation, and survival (Misawa et al. 2008).

Methylation of the *CDHI* gene promoter has been reported in tongue cancer (Chang et al. 2002), salivary gland adenoid cystic carcinoma (Zhang et al. 2007a), and nonmetastatic oral cancer as an early event (De Moraes et al. 2008; Maeda et al. 2007a; Yeh et al. 2002).

Expression of the *RAR β* gene has been studied in primary tissue specimens of different anatomical sites from patients with HNSCC and a strong correlation was found between hypermethylation and reduced expression of *RAR β 2* (Youssef et al. 2004). In particular, significantly lower hypermethylation and higher *RAR β 2* mRNA expression levels when compared to the tumors located at other sites of the head and neck were observed in tumors from the hypopharynx (Olasz et al. 2007) and salivary duct or acinic cell carcinomas displaying *RASSF1* methylation (Williams et al. 2006).

Genes with different functions

CHFR is a putative early mitotic checkpoint gene which causes a delay in chromosome condensation in response to mitotic stress. In a study, aberrant promoter methylation of the *CHFR* gene was reported in patients with OSCC, while the gene was methylated minimally in the surrounding normal mucosa and no methylation was observed in the *CHFR* promoter in a healthy cohort (Baba et al. 2009; Toyota et al. 2003).

The *HIC1* gene plays a role in the regulation of transcription. A study using MSP has reported that *HIC1* is highly (95%) methylated in HNSCC and reexpression of the gene was associated with decreased aggressiveness (Brieger et al. 2010). On the other hand, in a recent study from our group, no significant methylation of the *HIC1* gene was observed in patients with HNC using a more sensitive technique (Yáñez et al. 2011).

The *CYGB* gene was first described as an intracellular globin of unknown function (Burmester et al. 2002). *CYGB* downregulation is a key event in the familial cancer syndrome of the upper aerodigestive tract. Increased expression of the *CYGB* gene displays an inverse correlation with promoter methylation and a strong correlation with tumor hypoxia. It has been consistently associated with aggressive tumors in oral and oropharyngeal squamous cell carcinoma when compared with histologically tumor-free surgical margins (Shaw et al. 2009).

In individual studies, aberrant methylation of *RBI* (Kishi et al. 2005) and *14-3-3 sigma* (Uchida et al. 2004; Gasco et al. 2002) in salivary gland cancer, *Apaf-1* (Huang et al. 2004) and *DAPK* (Zhang and Kong 2004) in laryngeal squamous cell carcinoma, *TSC2* (Chakraborty et al. 2008), *SFRP1*, *SFRP2*, *SFRP5* (Sogabe et al. 2008), *RECK* (Long et al. 2008), *EpCAM* (Shiah et al. 2009), *MTNR1A* (Nakamura et al. 2008), *IKKalpha* (Maeda et al. 2007b), *PRTFDC1* (Suzuki et al. 2007), *LRP1B* (Nakagawa et al. 2006), *DBCCR1* (Gao et al. 2004), and *14-3-3 sigma* (Gasco et al. 2002) in OSCC, *PGP9.5* (Tokumaru et al. 2008), *C/EBPalpha* (Bennett et al. 2007), *LHX6* (Estécio et al. 2006), *STAT1* (Xi et al. 2006), *TIG1* (Tokumaru et al. 2005), *TCF21* (Smith et al. 2006), *SOCS3* (Weber et al. 2005), *p15* (Chang et al. 2004), and *ATM* (Ai et al. 2004) genes in patients with HNC have also been reported.

miR-137 plays an important role in the cell cycle control. It has been shown that *miR-137* and *miR-193a* are epigenetically silenced during oral carcinogenesis (Kozaki et al. 2008). Methylation of *miR-137* has been reported in squamous cell carcinoma tissue and oral rinse samples and was associated with gender and inversely associated with body mass index (Langevin et al. 2010).

Specific lysine residues in histone tails are methylated, providing an epigenetic marker that modulates biological functions changing the heterochromatin structure and leading to tumor development. H3K4 histone methylation was investigated in OSCC, dysplastic lesions, and normal tissue samples (Piyathilake et al. 2005). The levels of H3K4me2 and H3K4me3 displayed striking variations in OSCC when compared with normal tissue and leukoplakias. The me2 levels were increased while the me3 levels decreased in the tumors (Mancuso et al. 2009).

Nasopharyngeal carcinoma and studies of TSG gene panels

Nasopharyngeal carcinoma (NPC) is a rare malignancy with unique genetic, viral, and environmental characteristics that distinguish it from other types of head and neck carcinoma. It has a different etiology, epidemiology, prognosis, and therapy. The clinical management of NPC remains challenging largely due to the lack of early detection strategies for this tumor (Loyo et al. 2011; Razak et al. 2010).

A recent study investigating a panel of 18 marker genes in nasopharyngeal tumors has shown that the methylation status of the *AIM1*, *APC*, *CALCA*, *DCC*, *DLEC*, *DLC1*, *ESR*, *FHIT*, *KIF1A*, and *PGP9.5* genes were significantly associated with NPC when compared with other tumors or the benign nasopharyngeal biopsy samples (Loyo et al. 2011).

In an 11-gene panel, promoter methylation levels of *CDH1*, *p15*, *THBS1*, *RASSF1A*, *MLH1*, *MGMT*, *p16*, and

TP73 genes were significantly higher in the tumor samples from patients with NPC when compared with the lymphocytes from the same individuals (Wong et al. 2003a).

Using the discovery approach after expression profiling among eight potential candidate TSG, promoter methylation of only three genes (*CCNA1*, *RARRES1*, and *HRASLS*) have been significantly associated with NPC (Yanatsaneejit et al. 2008).

Promoter methylation of the *RASSF1A*, *DAPK*, and *RARβ2* genes was analyzed by MSP in primary NPC tumors and normal nasopharyngeal epithelia. All genes were highly methylated in tumor tissue, whereas methylation was not observed in the normal nasopharyngeal tissue. Methylation of the three genes was significantly associated with lymph node involvement. *RASSF1A* and *RARβ2* methylation also correlated with age at diagnosis, T stage, and histological type (Fendri et al. 2009). Epigenetic silencing of cellular retinol-binding proteins, *CRBPI*, *CRBP1V*, and *RARβ2* are also commonly observed in NPC tumor samples (Kwong et al. 2005a, 2002).

High methylation frequencies for the *DAPK*, *RASSF1A*, *CDH1*, and *p16* genes are frequently observed in NPC tumors (Kwong et al. 2002; Chang et al. 2003a). In contrast to HNSCC (Dikshit et al. 2007), in NPC, no change has been reported in the *RUNX3* promoter region, whereas the *p16*, *RASSF1A*, *CDH1*, and *hMLH1* gene promoters were frequently methylated (Tan et al. 2006).

In the patients with NPC from Southeast Asia but not from North Africa, methylation of *p16*, *DLEC1*, *BLU*, and *CDH1* genes were found to be associated with the juvenile and adult forms of the disease. Strong correlations were observed between aberrant promoter methylation of the *CDH1* and *BLU* genes and lymph node invasion (Li et al. 2003a, b) or undifferentiated tumors, respectively (Ayadi et al. 2008).

Single-gene studies in NPC

Tumor suppressor genes

WIF1 is a highly conserved gene on chromosome 12 and encodes a protein of the sFRP family, which inhibits the Wnt signaling pathway (Kawano and Kypta 2003). Inhibition of Wnt signaling induces apoptosis and inhibits tumor growth in many cancer types (He et al. 2004). Silencing of the *WIF1* gene by hypermethylation may result in the activation of some tumors (Suzuki et al. 2004; Caldwell et al. 2004; Ai et al. 2006; Taniguchi et al. 2005). The *WIF1* promoter region is highly methylated in nasopharyngeal tumors, whereas no methylation is observed in the normal mucosa (Fendri et al. 2010; Chan et al. 2007). *WIF1* methylation has been found to be associated with tumor size, node involvement and metastasis, and age (Fendri et al. 2010).

Expression of the *MIPOL1* gene is also downregulated in some NPC tumors via promoter hypermethylation and allelic loss (Cheung et al. 2009). Likewise, *DAB2* is frequently methylated in NPC, which correlates with the loss of expression in NPC tumors (Tong et al. 2010).

Two studies investigating the *RASSF1A* gene have shown that the gene is highly methylated in primary NPC but not in normal nasopharyngeal epithelia (Wang et al. 2009; Lo et al. 2001). It has been suggested that aberrant hypermethylation of *RASSF1A* and high Epstein–Barr virus (EBV) load may play an important role in NPC carcinogenesis (Zhou et al. 2005).

Methylation of *CDHI* is more frequently observed in advanced stages of NPC (Niemhom et al. 2008). Hypermethylation of *CDHI* promoter and presence of EBV are predominantly detected in undifferentiated and nonkeratinizing NPC compared to squamous cell NPC. Most of the NPC samples demonstrating *CDHI* hypermethylation were EBV-positive, whereas the EBV genome and hypermethylation were not detected in normal nasopharyngeal tissue when *CDHI* methylation was absent, indicating a correlation between *CDHI* hypermethylation and EBV infection (Niemhom et al. 2008; Krishna et al. 2005; Li et al. 2003a, b; Tsao et al. 2003; Kao et al. 2002).

Genes with various functions

14-3-3 sigma, the downstream target of *p53*, is a negative regulator of cell cycle G2–M phase checkpoint in response to DNA damage. By MSP, 100% methylation of *14-3-3 sigma* was shown in tumor tissue but not in any of adjacent normal nasopharyngeal epithelial tissue (Yi et al. 2009). Analysis by real-time PCR, Western blotting, and immunohistochemistry have revealed that *14-3-3 sigma* expression is downregulated or absent in NPC samples displaying high methylation. In addition, hypermethylation of *14-3-3 sigma* has been associated with lymph node and distant metastasis.

Methylation of the *PGP9.5* gene is frequently detected in primary NPC but only minimally observed in normal nasopharyngeal tissue, indicating that the methylation-mediated silencing of *PGP9.5* may be important in nasopharyngeal carcinogenesis (Li et al. 2010). The *EDNRB* gene, located on chromosome 13q22, was highly methylated in primary NPC tumor samples, while no methylation was observed in normal nasopharyngeal epithelia (Zhou et al. 2007; Lo et al. 2002). In patients with NPC, high methylation of the *LARS2* gene, which is located at the chromosome 3 common eliminated region-1 (*C3CER1*) on 3p21.3, has been reported (Zhou et al. 2009).

Several genes which have been studied in gene panels were also evaluated in single-gene studies. *RASSF2* (Zhang et al. 2007b), *DLC1* (Seng et al. 2007), *DAPK* (Kong et al. 2006; Wong et al. 2002), *CHFR* (Cheung et al. 2005), *TIG1*

(Kwong et al. 2005b), *BLU* (Qiu et al. 2004; Liu et al. 2003a, b), and *p16* (Lo et al. 1996) are among those. The corresponding data are given in Table 3. Other newly identified TSG are *IRF8* (Lee et al. 2008), *ADAMTS18*, which is a novel gene located on 16q23 (Jin et al. 2007), *LTF* (Yi et al. 2006), *CDH13* (Sun et al. 2007), *PCDH10* (Ying et al. 2006), *TSLC1* (Hui et al. 2003), *HIN-1* (Wong et al. 2003b), and *RIZ1* (Chang et al. 2003b). The *GNAT1* gene has been shown to be methylated not only in all primary NPC tissues but also in 80% of tissue samples with chronic nasopharyngitis (Yi et al. 2007).

Conclusions

Biomarkers predicting clinical response, tumor recurrence, or patient survival are not available for HNC. Further studies are needed to identify new biomarkers for early detection and prediction of the therapeutic response or prognosis. Follow-up studies using quantitative MSP analysis, global methylation profiling, and detailed analysis of downstream DNA repair genes regulated by promoter methylation may provide new insight into the issue. Considering the great heterogeneity of HNC, a combination of multiple genes for analysis may provide a higher coverage for diverse tumors than the analysis of a single gene (Carvalho et al. 2008). Recent data indicate that promoter hypermethylation of the *KIF1A* and *EDNRB* genes is a frequent event in primary HNSCC and combining only the *KIF1A* and *EDNRB* genes provides a higher specificity and sensitivity than using a panel of 10 different genes (Demokan et al. 2010). Preferential methylation of these genes in salivary rinses from HNSCC patients may provide a promising potential biomarker for the disease. Other genes investigated frequently and found to display significant differential methylation are *RASSF1A*, *DAPK1*, *MGMT*, *RAR β* , *CDHI*, *hMLH1*, and *CHFR*, although a wide range of different methylation ratios have been reported. These variations most probably result from the differences in the sensitivity of the methods, variations in the processing of the samples, and composition of the patient cohorts.

Methylation analysis has the additional advantage that methylation patterns are not affected by external factors or temporary physiological changes. They persist and are usually increased during disease progression. The higher specificity and sensitivity provides a suitable tool to obtain predictive or prognostic information. So far, the information about DNA methylation has not translated into useful and reliable markers for HNC in the clinical practice. However, given the sensitive and high-throughput quantitative methodologies for methylation analysis, specific markers for HNC will certainly

Table 3 Methylation of different genes reported in individual studies

Gene	Name	Function	Tumor type	Method	Samples	Methylation range (%)
<i>ADAM23</i>	ADAM metalloproteinase domain 23	Cell-cell and cell-matrix interactions	LC (Calmon et al. 2007)	MSP (Calmon et al. 2007)	T (Calmon et al. 2007)	42
<i>ADAMTS18</i>	A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 18	Tumor suppression	NPC (Jin et al. 2007)	MSP (Jin et al. 2007)	(T,NE) (Jin et al. 2007)	70
<i>AIM1</i>	Absent in melanoma 1	Tumor suppression	NPC (Loyo et al. 2011)	QMSP (Loyo et al. 2011)	T (Loyo et al. 2011)	30
<i>APAF1</i>	Apoptotic peptidase activating factor 1	Apoptosis	LC (Huang et al. 2004)	MSP (Huang et al. 2004)	T (Huang et al. 2004)	40
<i>ATM</i>	Ataxia telangiectasia mutated	Regulating DNA damage response mechanism	HNC (Ai et al. 2004)	MSP (Ai et al. 2004)	(T,NE) (Ai et al. 2004)	25
<i>BMP2A</i>	Bone morphogenetic protein 2A	Induction of cartilage and bone formation	HNSCC (Tokumaru et al. 2004)	BS (Tokumaru et al. 2004)	T (Tokumaru et al. 2004)	25
<i>C/EBPalpha</i>	Tumor suppressor CCAAT enhancer binding protein alpha	Transcriptional regulation	HNC (Bennett et al. 2007)	COBRA (Bennett et al. 2007)	(T,MN) (Bennett et al. 2007)	68
<i>CALCA</i>	Calcitonin-related polypeptide alpha	Calcium regulation and phosphorus metabolism	NPC (Loyo et al. 2011)	QMSP (Loyo et al. 2011)	T (Loyo et al. 2011)	44
<i>CHD13</i>	Cadherin 13	Calcium-dependent cell adhesion	NPC (Sun et al. 2007)	MSP (Sun et al. 2007)	(T,NE) (Sun et al. 2007)	89.7
<i>CRABP2</i>	Cellular retinoic acid binding protein 2	Retinoic acid-mediated regulation of human skin growth and differentiation	HNSCC (Calmon et al. 2009)	MSP (Calmon et al. 2009)	(T,L) (Calmon et al. 2009)	58
<i>CRBPI</i>	Cellular retinol-binding protein type I	Intracellular transport of retinol	NPC (Kwong et al. 2005b)	MSP (Kwong et al. 2005b)	T (Kwong et al. 2005b)	87.8
<i>CRBPIV</i>	Cellular retinol-binding protein type IV	Intracellular transport of retinol	NPC (Kwong et al. 2005b)	MSP (Kwong et al. 2005b)	T (Kwong et al. 2005b)	54
<i>CYGB</i>	Cytoglobin	Transfer of oxygen from arterial blood to the brain	OSCC (Shaw et al. 2006)	PS (Shaw et al. 2006)	(T,MN) (Shaw et al. 2006)	65
<i>CYP11A1</i>	Cytochrome p450 family 1A	Carcinogen metabolism	HNC (Sharma et al. 2010)	MSP (Sharma et al. 2010)	(T,NE) (Sharma et al. 2010)	39.7
<i>CYP2A13</i>	Cytochrome P450, family 2, subfamily A, polypeptide 13	Carcinogen metabolism	HNC (Sharma et al. 2010)	MSP (Sharma et al. 2010)	(T,NE) (Sharma et al. 2010)	27.4
<i>DAB2</i>	Human disabled-2	Signal transduction	NPC (Tong et al. 2010)	MSP (Tong et al. 2010)	T (Tong et al. 2010)	65
<i>DBCCR1</i>	Deleted in bladder cancer 1	Inhibition of cell proliferation, involvement in cell death, and regulation of plasminogen pathway	(OSCC, PM-OCL) (Gao et al. 2004)	MSP (Gao et al. 2004)	(T,MN) (Gao et al. 2004)	44
<i>EpCAM</i>	Epithelial cell adhesion molecule	Homotypic calcium-independent cell adhesion	OSCC (Shiah et al. 2009)	MSP (Shiah et al. 2009)	T (Shiah et al. 2009)	51
<i>ESR</i>	Estrogen receptor alpha	Hormone binding, DNA binding and activation of transcription	NPC (Loyo et al. 2011)	QMSP (Loyo et al. 2011)	T (Loyo et al. 2011)	26
<i>FancB</i>	Fanconi anemia, complementation group B	DNA repair	HNSCC (Smith et al. 2010)	QMSP (Smith et al. 2010)	(T,NE) (Smith et al. 2010)	31
<i>GALR1</i>	Galanin receptor 1	Tumor suppression	HNSCC (Misawa et al. 2008)	(MSP, BS) (Misawa et al. 2008)	T (Misawa et al. 2008)	38
<i>GNAT1</i>	Guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 1	Signal transduction	NPC (Yi et al. 2007)	MSP (Yi et al. 2007)	(T,CINT) (Yi et al. 2007)	100

Table 3 (continued)

Gene	Name	Function	Tumor type	Method	Samples	Methylation range (%)
<i>GSTM1</i>	Glutathione S-transferase mu 1	Carcinogen metabolism	HNC (Sharma et al. 2010)	MSP (Sharma et al. 2010)	(T,NE) (Sharma et al. 2010)	58.1
<i>HIC1</i>	Hypermethylated in cancer 1	Transcriptional regulation	HNSCC (El-Naggar et al. 1997)	MSP (El-Naggar et al. 1997)	T (El-Naggar et al. 1997)	95
<i>HRASLS</i>	HRAS-like suppressor	Formation of peripheral nerve trajectories	NPC (Yanatsanejit et al. 2008)	MSP-COBRA (Yanatsanejit et al. 2008)	(T,NE,L) (Yanatsanejit et al. 2008)	17
<i>IKKalpha</i>	IkappaB kinase-alpha	NF-kappaB signaling pathway	OSCC (Maeda et al. 2007b)	BS (Maeda et al. 2007b)	(T,NE) (Maeda et al. 2007b)	63
<i>IRF8</i>	Interferon regulatory factor 8	Transcriptional regulation	NPC (Lee et al. 2008)	MSP (Lee et al. 2008)	T (Lee et al. 2008)	78
<i>LARS2</i>	Leucyl-tRNA synthetase 2, mitochondrial	The action of a catalyst charging of tRNA ^{Leu(UUR)} with leucine	NPC (Zhou et al. 2009)	PCR-SSCP (Zhou et al. 2009)	T (Zhou et al. 2009)	64
<i>LHX6</i>	LIM homeobox 6	The specification of cortical interneuron subtypes and in the migration of GABAergic interneuron precursors from the subpallium to the cerebral cortex	HNC (Estéicio et al. 2006)	(MS/AP-PCR) (Estéicio et al. 2006), (COBRA) (Estéicio et al. 2006)	(T,NE) (Estéicio et al. 2006)	65.6
<i>LRP1B</i>	Low-density lipoprotein receptor-related protein 1B	Process of receptor-mediated endocytosis	OSCC (Nakagawa et al. 2006)	COBRA (Nakagawa et al. 2006)	T (Nakagawa et al. 2006)	43
<i>LTF</i>	Lactotransferrin	Antimicrobial activity	NPC (Yi et al. 2006)	MSP (Yi et al. 2006)	(T,CINT) (Yi et al. 2006)	63.6
<i>MALTI</i>	Mucosa-associated lymphoid tissue 1	Signal transduction	OSCC (Chiba et al. 2009)	MSP (Chiba et al. 2009)	(T,NE) (Chiba et al. 2009)	83
<i>MINT2</i>	Methylated in tumor-2	Tumor suppression	OSCC (Ogi et al. 2002)	MSRE (Ogi et al. 2002)	T (Ogi et al. 2002)	8
<i>MINT27</i>	Methylated in tumor-27	Tumor suppression	OSCC (Ogi et al. 2002)	MSRE (Ogi et al. 2002)	T (Ogi et al. 2002)	16
<i>MIPOL1</i>	Mirror-image polydactyly 1	Tumor suppression	NPC (Cheung et al. 2009)	MSP (Cheung et al. 2009)	(T,MN) (Cheung et al. 2009)	63
<i>MTIG</i>	Metallothionein 1G	Response to heavy metals	HNSCC (Tokumaru et al. 2004)	BS (Tokumaru et al. 2004)	T (Tokumaru et al. 2004)	25
<i>MTNR1A</i>	Melatonin receptor 1 A	Reproductive and circadian actions of melatonin	OSCC (Nakamura et al. 2008)	(COBRA, MSP) (Nakamura et al. 2008)	(T,MN) (Nakamura et al. 2008)	62
<i>MX1</i>	Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse)	Regulation of the calcium channel activity of TRPCs and activation against influenza virus and VSV, a rhabdovirus	HNSCC (Calmon et al. 2009)	MSP (Calmon et al. 2009)	(T,L) (Calmon et al. 2009)	46
<i>NDRG2</i>	N-myc downstream-regulated gene 2	Neurite outgrowth	(OSCC, PM-OCL) (Furuta et al. 2010)	MSP (Furuta et al. 2010)	T (Furuta et al. 2010)	80
<i>NISCH</i>	Nischarin	Membrane-associated mediator of the IIR signaling	HNSCC (Hoque et al. 2008)	QMSP (Hoque et al. 2008)	T (Hoque et al. 2008) (SA-H,NE) (Hoque et al. 2008)	36

Table 3 (continued)

Gene	Name	Function	Tumor type	Method	Samples	Methylation range (%)
<i>NmU</i>	Neuromedin U	Stimulation of contractions of the ileum and urinary bladder	HNSCC (Tokumaru et al. 2004)	BS (Tokumaru et al. 2004)	T (Tokumaru et al. 2004)	20
<i>OGDHL</i>	Oxoglutarate dehydrogenase-like	Citric acid cycle	HNSCC (Hoque et al. 2008)	QMSP (Hoque et al. 2008)	T (Hoque et al. 2008) (SA-H,NE)	8
<i>PAK3</i>	p21-activated protein kinase 3	Cytoskeleton reorganization and nuclear signaling	HNSCC (Hoque et al. 2008)	QMSP (Hoque et al. 2008)	T (Hoque et al. 2008) (SA-H,NE)	52
<i>PCDH10</i>	Protocadherin 10	Calcium-dependent cell adhesion	NPC (Ying et al. 2006)	MSP (Ying et al. 2006)	T (Ying et al. 2006)	82
<i>PRTFDC1</i>	Phosphoribosyl transferase domain containing 1	Tumor suppression	OSCC (Suzuki et al. 2007)	COBRA (Suzuki et al. 2007)	T (Suzuki et al. 2007)	17
<i>RASSF4</i>	Ras association (RalGDS/AF-6) domain family member 4	Tumor suppression	HNSCC (Steinmann et al. 2009)	COBRA (Steinmann et al. 2009)	(T,MN) (Steinmann et al. 2009)	13
<i>RASSF5</i>	Ras association (RalGDS/AF-6) domain family member 5	Tumor suppression	HNSCC (Steinmann et al. 2009)	COBRA (Steinmann et al. 2009)	(T,MN) (Steinmann et al. 2009)	58
<i>RB1</i>	Retinoblastoma 1	Tumor suppression	SGC (Kishi et al. 2005)	MSP (Kishi et al. 2005)	T (Kishi et al. 2005)	41.7
<i>RECK</i>	Reversion-inducing cysteine-rich protein with kazal motifs	Suppression of tumor invasion and metastasis	OSCC (Long et al. 2008)	MSP (Long et al. 2008)	(T,MN,NE) (Long et al. 2008)	52
<i>RIZ1</i>	Retinoblastoma protein-interacting zinc finger protein	Transcriptional activation	NPC (Chang et al. 2003a)	MSP (Chang et al. 2003a)	(T, L,SA-P) (Chang et al. 2003a)	60
<i>ROBO1</i>	Roundabout, axon guidance receptor, homolog 1 (<i>Drosophila</i>)	Tumor suppression	(HNSCC)(Ghosh et al. 2009) (PM-HNL) (Ghosh et al. 2009)	MSRE (Ghosh et al. 2009)	T (Ghosh et al. 2009)	21
<i>SFRP2</i>	Secreted protein 2	Inhibition of Wnt signaling	OSCC (Sogabe et al. 2008)	MSP (Sogabe et al. 2008)	(T, MN) (Sogabe et al. 2008)	36
<i>SFRP5</i>	Secreted protein 5	Inhibition of Wnt signaling	OSCC (Sogabe et al. 2008)	MSP (Sogabe et al. 2008)	(T, MN) (Sogabe et al. 2008)	16
<i>SOC33</i>	Suppressor of cytokine signaling 3	Signal transduction	(HNC, PM-HNC) (Weber et al. 2005)	MSP (Weber et al. 2005)	(T,MN,LN) (Weber et al. 2005)	90
<i>STAT1</i>	Signal transducer and activator of transcription 1	Signal transduction	HNC (Xi et al. 2006)	MSP (Xi et al. 2006)	(TL) (Xi et al. 2006)	75
<i>SYK</i>	Spleen tyrosine kinase	Signal transduction	OSCC (Ogane et al. 2009)	QMSP (Ogane et al. 2009)	(T,MN) (Ogane et al. 2009)	63
<i>TGFBR-1</i>	Transforming growth factor, beta receptor 1	Signal transduction	HNSCC (Muñoz-Antonia et al. 2009)	MSP (Muñoz-Antonia et al. 2009)	T (Muñoz-Antonia et al. 2009)	62
<i>TCF21</i>	Transcription factor 21	Epithelial–mesenchymal interactions	HNC (Smith et al. 2006)	COBRA (Smith et al. 2006)	(T,MN) (Smith et al. 2006)	76
<i>TSC2</i>	Tuberous sclerosis 2	Tumor suppression	OSCC (Chakraborty et al. 2008)	COBRA (Chakraborty et al. 2008)	(T,MN) (Chakraborty et al. 2008)	100
<i>TSLC1</i>	Tumor suppressor in lung cancer	Tumor suppression	NPC (Hui et al. 2003)	MSP (Hui et al. 2003)	(T,NE) (Hui et al. 2003)	34.2

emerge by careful evaluation and combination of different marker panels to achieve a high sensitivity for the disease. Over the next years, clinical tests based on diagnostic and therapeutic methylation markers will certainly be available and will be used for the assessment of prognosis, treatment planning, and to predict the response.

Future studies aiming to determine the causative role and significance of these epigenetic alterations may provide important clues into the mechanism and contribution of the specific events and help to establish a sequence of methylation events during tumor development associated with different stages of head and neck carcinogenesis. Since tumor-specific DNA can be easily detected in blood, serum, and saliva, methylation analysis can be used as a noninvasive method for the early detection using a panel of the genes specific for the disease. Furthermore, epigenetic silencing of the genes offers new therapeutic approaches using demethylating agents. Analysis of genome-wide methylation profiles by new high-throughput technologies which enable simultaneous analysis of thousands of genetic loci will certainly help to identify highly specific novel methylation biomarkers.

Conflict of interest The authors declare that they have no conflicts of interest.

References

- Agnese V, Corsale S, Calò V, Augello C, Bruno L, Calcara D, Crosta A, Rodolico V, Rinaldi G, Cicero G, Latteri F, Agrusa A, Morello V, Adamo V, Altavilla G, Di Fede G, Fiorentino E, Grassi N, Latteri MA, Valerio MR, Tomasino RM, Colucci G, Bazan V, Russo A, Gruppo Oncologico dell'Italia Meridionale (2006) Significance of p16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. *Ann Oncol* 17(Suppl 7):137–141
- Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, Hanna E, Fan CY (2003) The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. *Mod Pathol* 16:944–950
- Ai L, Vò QN, Zuo C, Li L, Ling W, Suen JY, Hanna E, Brown KD, Fan CY (2004) Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. *Cancer Epidemiol Biomarkers Prev* 13:150–156
- Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. *Carcinogenesis* 27:1341–1348
- Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S (2006) Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. *Int J Cancer* 119:288–296
- Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, Ghorbel A, Daoud J, Frikha M, Busson P, Hammami A (2008) Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. *Anticancer Res* 28:2161–2167
- Azarschab P, Stembalska A, Loncar MB, Pfister M, Sasiadek MM, Blin N (2003) Epigenetic control of E-cadherin (CDH1) by CpG methylation in metastasising laryngeal cancer. *Oncol Rep* 10:501–503
- Baba S, Hara A, Kato K, Long NK, Hatano Y, Kimura M, Okano Y, Yamada Y, Shibata T (2009) Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas. *Oncol Rep* 22:1173–1179
- Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y (1995) Cloning, mapping and expression of PEBP2aC, a third gene encoding the mammalian runt domain. *Gene* 159:245–248
- Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, Schuller DE, Weber F, Eng C, Plass C (2007) Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. *Cancer Res* 67:4657–4664
- Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D, Plass C (2008) Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. *Cancer Res* 68:4494–4499
- Bennett KL, Romigh T, Eng C (2009) Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis. *Cancer Res* 69:9301–9305
- Bennett KL, Lee W, Lamarre E, Zhang X, Seth R, Scharpf J, Hunt J, Eng C (2010) HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. *Genes Chromosomes Cancer* 49:319–326
- Brieger J, Pongsapich W, Mann SA, Hedrich J, Fruth K, Pogozelski B, Mann WJ (2010) Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma. *Oral Oncol* 46:678–683
- Burmester T, Ebner B, Weich B, Hankeln T (2002) Cytoglobin: a novel globin type ubiquitously expressed in vertebrate tissues. *Mol Biol Evol* 19:416–421
- Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. *Cancer Res* 64:883–888
- Calmon MF, Colombo J, Carvalho F, Souza FP, Filho JF, Fukuyama EE, Camargo AA, Caballero OL, Tajara EH, Cordeiro JA, Rahal P (2007) Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. *Cancer Genet Cytogenet* 173:31–37
- Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, Pinheiro DG, Torres C, de Carvalho AF, Cury PM, Nunes FD, Nishimoto IN, Soares FA, da Silva AM, Kowalski LP, Brentani H, Zanelli CF, Silva WA Jr, Rahal P, Tajara EH, Carraro DM, Camargo AA, Valentini SR (2009) Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. *Neoplasia* 11:1329–1339
- Cao J, Zhou J, Gao Y, Gu L, Meng H, Liu H, Deng D (2009) Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. *Clin Cancer Res* 15:5178–5183
- Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jerónimo C, Henrique R, Nayak CS, Park HL, Brait MR, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Westra W, Sidransky D, Moon CS, Califano JA (2006) Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated

- by promoter hypermethylation in head and neck squamous cell carcinoma. *Cancer Res* 66:9401–9407
- Carvalho AL, Jeronimo C, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA (2008) Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. *Clin Cancer Res* 14:97–107
- Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A (2008) Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. *BMC Cancer* 8:163
- Chan SL, Cui Y, van Hasselt A, Li H, Srivastava G, Jin H, Ng KM, Wang Y, Lee KY, Tsao GS, Zhong S, Robertson KD, Rha SY, Chan AT, Tao Q (2007) The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. *Lab Invest* 87:644–650
- Chang HW, Chow V, Lam KY, Wei WI, Yuen A (2002) Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. *Cancer* 94:386–392
- Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP (2003a) Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. *Clin Cancer Res* 9:1033–1038
- Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP (2003b) Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharyngeal carcinoma patient. *Int J Cancer* 105:851–855
- Chang HW, Ling GS, Wei WI, Yuen AP (2004) Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. *Cancer* 101:125–132
- Chen K, Sawhney R, Khan M, Benninger MS, Hou Z, Sethi S, Stephen JK, Worsham MJ (2007) Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 133:1131–1138
- Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung A, Tsao SW, Wang Q, Yeun PW, Lo KW, Jin DY, Wang X (2005) Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. *Mol Carcinog* 43:237–245
- Cheung AK, Lung HL, Ko JM, Cheng Y, Stanbridge EJ, Zbarovsky ER, Nicholls JM, Chua D, Tsao SW, Guan XY, Lung ML (2009) Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in nasopharyngeal carcinoma. *Proc Natl Acad Sci USA* 106:14478–14483
- Chiba T, Maeda G, Kawashiri S, Kato K, Imai K (2009) Epigenetic loss of mucosa-associated lymphoid tissue 1 expression in patients with oral carcinomas. *Cancer Res* 69:7216–7223
- Crowe DL, Hacia JG, Hsieh CL, Sinha UK, Rice H (2002) Molecular pathology of head and neck cancer. *Histol Histopathol* 17:909–914
- Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V, Ben-Yehuda D (2009) Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. *Oral Dis* 15:206–213
- Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL (2007) Clinical implications and utility of field cancerization. *Cancer Cell Int* 7:2
- De Moraes RV, Oliveira DT, Landman G, de Carvalho F, Caballero O, Nonogaki S, Nishimoto I, Kowalski LP (2008) E-cadherin abnormalities resulting from CpG methylation promoter in metastatic and nonmetastatic oral cancer. *Head Neck* 30:85–92
- De Schutter H, Geeraerts H, Verbeke E, Nuyts S (2009) Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. *Oncol Rep* 21:507–513
- Demokan S, Suoglu Y, Demir D, Gozeler M, Dalay N (2006) Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. *Ann Oncol* 17:995–999
- Demokan S, Chang X, Chuang A, Mydlarz WK, Kaur J, Huang P, Khan Z, Khan T, Ostrow KL, Brait M, Hoque MO, Liegeois NJ, Sidransky D, Koch W, Califano JA (2010) KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. *Int J Cancer* 127:2351–2359
- Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Peñuela JM, Boffetta P, Merletti F (2007) Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. *Cancer* 110:1745–1751
- Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D (2003) Epigenetic inactivation of RASSF1A in head and neck cancer. *Clin Cancer Res* 9:3635–3640
- Durr ML, Mydlarz WK, Shao C, Zahurak ML, Chuang AY, Hoque MO, Westra WH, Liegeois NJ, Califano JA, Sidransky D, Ha PK (2010) Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. *PLoS One* 5:e10828
- El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG (1997) Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. *Am J Pathol* 151:1767–1774
- Estécio MR, Youssef EM, Rahal P, Fukuyama EE, Góis-Filho JF, Maniglia JV, Goloni-Bertollo EM, Issa JP, Tajara EH (2006) LHX6 is a sensitive methylation marker in head and neck carcinomas. *Oncogene* 25:5018–5026
- Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R (2009) Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. *Cancer Biol Ther* 8:444–451
- Fendri A, Khabir A, Hadri-Guiga B, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R (2010) Epigenetic alteration of the Wnt inhibitory factor-1 promoter is common and occurs in advanced stage of Tunisian nasopharyngeal carcinoma. *Cancer Invest* 28:896–903
- Furniss CS, Marsit CJ, Houseman EA, Eddy K, Kelsey KT (2008) Line region hypomethylation is associated with lifestyle and differs by human papillomavirus status in head and neck squamous cell carcinomas. *Cancer Epidemiol Biomarkers Prev* 17:966–971
- Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K (2010) NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. *Biochem Biophys Res Commun* 391:1785–1791
- Gao S, Worm J, Guldborg P, Eiberg H, Kroghdahl A, Sørensen JA, Liu CJ, Reibel J, Dabelsteen E (2004) Loss of heterozygosity at 9q33 and hypermethylation of the DBCCR1 gene in oral squamous cell carcinoma. *Br J Cancer* 91:760–764
- Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, Jiang L, Chen Q (2009) Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. *J Cancer Res Clin Oncol* 135:739–747
- Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G, Merlano M, Farrell PJ, Tavassoli M, Gusterson B, Crook T (2002) Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. *Cancer Res* 62:2072–2076
- Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roychoudhury S, Panda CK (2009) Alterations of ROBO1/DUTT1 and ROBO2

- loci in early dysplastic lesions of head and neck: clinical and prognostic implications. *Hum Genet* 125:189–198
- Ginos MA, Page GP, Michalowicz BS, Patel KJ, Völker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM (2004) Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. *Cancer Res* 64:55–63
- González MV, Pello MF, López-Larrea C, Suárez C, Menéndez MJ, Coto E (1997) Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. *J Clin Pathol* 50:509–512
- Guerrero-Preston R, Báez A, Blanco A, Berdasco M, Fraga M, Esteller M (2009) Global DNA methylation: a common early event in oral cancer cases with exposure to environmental carcinogens or viral agents. *P R Health Sci J* 28:24–29
- Guo XL, Sun SZ, Wang WX, Wei FC, Yu HB, Ma BL (2007) Alterations of p16INK4a tumour suppressor gene in mucoepidermoid carcinoma of the salivary glands. *Int J Oral Maxillofac Surg* 36:350–353
- Ha PK, Califano JA (2003) The molecular biology of mucosal field cancerization of the head and neck. *Crit Rev Oral Biol Med* 14:363–369
- Hall GL, Shaw RJ, Field EA, Rogers SN, Sutton DN, Woolgar JA, Lowe D, Liloglou T, Field JK, Risk JM (2008) p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. *Cancer Epidemiol Biomarkers Prev* 17:2174–2179
- Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT (2002) Patterns of gene promoter methylation in squamous cell cancer of the head and neck. *Oncogene* 21:4231–4236
- He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM (2004) A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. *Neoplasia* 6:7–14
- Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, Schuurin E, Begum S, Rosenbaum E, Ongenaert M, Yamashita K, Califano J, Westra W, van der Zee AG, Van Criekinge W, Sidransky D (2008) Genome-wide promoter analysis uncovers portions of the cancer methylome. *Cancer Res* 68:2661–2670
- Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, Kelsey KT (2007) Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 16:108–114
- Huang MJ, Yeh KT, Shih HC, Wang YF, Lin TH, Chang JY, Shih MC, Chang JG (2002) The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. *Int J Mol Med* 10:551–554
- Huang DF, Fu WN, Shang C, Xu ZM, Li ZG, Sun KL (2004) Expression and promoter methylation of Apaf-1 gene in laryngeal squamous cell carcinoma. *Yi Chuan Xue Bao* 31:1327–1331
- Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL (2009) Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. *Clin Cancer Res* 15:4174–4180
- Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP (2003) Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. *Mol Carcinog* 38:170–178
- Imai T, Toyota M, Suzuki H, Akino K, Ogi K, Sogabe Y, Kashima L, Maruyama R, Nojima M, Mita H, Sasaki Y, Itoh F, Imai K, Shinomura Y, Hiratsuka H, Tokino T (2008) Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. *Cancer Sci* 99:958–966
- Ishida E, Nakamura M, Ikuta M, Shimada K, Matsuyoshi S, Kirita T, Konishi N (2005) Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. *Oral Oncol* 41:614–622
- Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood* 103:1635–1640
- Jin H, Wang X, Ying J, Wong AH, Li H, Lee KY, Srivastava G, Chan AT, Yeo W, Ma BB, Putti TC, Lung ML, Shen ZY, Xu LY, Langford C, Tao Q (2007) Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. *Oncogene* 26:7490–7498
- Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 3:415–428
- Kao RH, Huang LC, Hsu YH (2002) Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma. *Anticancer Res* 22:4109–4113
- Kato K, Hara A, Kuno T, Mori H, Yamashita T, Toida M, Shibata T (2006) Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. *J Cancer Res Clin Oncol* 132:735–743
- Kaur J, Demokan S, Tripathi SC, Macha MA, Begum S, Califano JA, Ralhan R (2010) Promoter hypermethylation in Indian primary oral squamous cell carcinoma. *Int J Cancer* 127:2367–2373
- Kawano Y, Kypta Y (2003) Secreted antagonists of the Wnt signalling pathway. *J Cell Sci* 116:2627–2634
- Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH (2006) Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. *Cancer Res* 66:4049–4054
- Kishi M, Nakamura M, Nishimine M, Ikuta M, Kirita T, Konishi N (2005) Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. *Oral Oncol* 41:161–169
- Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S (2000) Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. *Hepatology* 32:970–979
- Kong WJ, Zhang S, Guo CK, Wang YJ, Chen X, Zhang SL, Zhang D, Liu Z, Kong W (2006) Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma. *Anticancer Drugs* 17:251–259
- Kordi-Tamandani DM, Moazeni-Roodi A, Rigi Ladez MA, Hashemi M, Birjandian E, Torkamanzehi A (2010) Analysis of methylation patterns and expression profiles of p14ARF gene in patients with oral squamous cell carcinoma. *Int J Biol Markers* 25:99–103
- Koscielny S, Dahse R, Ernst G, von Eggeling F (2007) The prognostic relevance of p16 inactivation in head and neck cancer. *ORL J Otorhinolaryngol Relat Spec* 69:30–36
- Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. *Cancer Res* 68:2094–2105
- Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC, Weghorst CM (2002) Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. *Cancer Res* 62:5295–5300
- Krishna SM, Kattoor J, Balaram P (2005) Down regulation of adhesion protein E-cadherin in Epstein–Barr virus infected nasopharyngeal carcinomas. *Cancer Biomark* 1:271–277
- Kumar V, Cotran R, Robbins SL (2000) Basic Pathology, 6th edn. WBSC, Philadelphia
- Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. *Clin Cancer Res* 8:131–137
- Kwong J, Lo KW, Chow LS, Chan FL, To KF, Huang DP (2005a) Silencing of the retinoid response gene TIG1 by promoter

- hypermethylation in nasopharyngeal carcinoma. *Int J Cancer* 113:386–392
- Kwong J, Lo KW, Chow LS, To KF, Choy KW, Chan FL, Mok SC, Huang DP (2005b) Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. *Neoplasia* 7:67–74
- Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E (2010) MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. *Carcinogenesis* 31:864–870
- Lee KY, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, Zeng YX, Wong AH, Wang X, Ying J, Srivastava G, Lung ML, Wang LD, Kwok TT, Levi BZ, Chan AT, Sung JJ, Tao Q (2008) Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. *Oncogene* 27:5267–5276
- Lee CH, Hung YJ, Lin CY, Hung PH, Hung HW, Shieh YS (2010) Loss of SFRP1 expression is associated with aberrant beta-catenin distribution and tumor progression in mucoepidermoid carcinoma of salivary glands. *Ann Surg Oncol* 17:2237–2246
- Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. *Cell* 109:113–124
- Li Z, Lin SX, Liang YJ (2003a) Detection of gene promoter methylation and mRNA, protein expression levels of E-cadherin in nasopharyngeal carcinoma. *Zhonghua Bing Li Xue Za Zhi* 32:25–30
- Li Z, Lin SX, Liang YJ (2003b) Influence of E-cadherin promoter methylation and mutation of beta-catenin on invasion and metastasis of nasopharyngeal carcinoma cells. *Zhonghua Zhong Liu Za Zhi* 25:238–242
- Li J, El-Naggar A, Mao L (2005) Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. *Cancer* 104:771–776
- Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, Zeng MS, Jia WH, Zeng YX, Chan AT, Cao Y (2010) The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. *Clin Cancer Res* 16:2949–2958
- Liu K, Huang H, Mukunyadzi P, Suen JY, Hanna E, Fan CY (2002) Promoter hypermethylation: an important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. *Otolaryngol Head Neck Surg* 126:548–553
- Liu K, Zuo C, Luo QK, Suen JY, Hanna E, Fan CY (2003a) Promoter hypermethylation and inactivation of hMLH1, a DNA mismatch repair gene, in head and neck squamous cell carcinoma. *Diagn Mol Pathol* 12:50–56
- Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, Long QX, Wang XZ, Zeng YX (2003b) Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. *Int J Cancer* 106:60–65
- Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC, Huang DP (1996) Hypermethylation of the p16 gene in nasopharyngeal carcinoma. *Cancer Res* 56:2721–2725
- Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. *Cancer Res* 61:3877–3881
- Lo KW, Tsang YS, Kwong J, To KF, Teo PM, Huang DP (2002) Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. *Int J Cancer* 98:651–655
- Long NK, Kato K, Yamashita T, Makita H, Toida M, Hatakeyama D, Hara A, Mori H, Shibata T (2008) Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. *Oral Oncol* 44:1052–1058
- Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, Chuang AY, Califano JA, Liégeois NJ, Begum S, Westra WH, Hoque MO, Tao Q, Sidransky D (2011) A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. *Int J Cancer* 128:1393–1403
- Maeda G, Chiba T, Aoba T, Imai K (2007a) Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. *Odontology* 95:24–29
- Maeda G, Chiba T, Kawashiri S, Satoh T, Imai K (2007b) Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression. *Clin Cancer Res* 13:5041–5047
- Mancuso M, Matassa DS, Conte M, Colella G, Rana G, Fucci L, Piscopo M (2009) H3K4 histone methylation in oral squamous cell carcinoma. *Acta Biochim Pol* 56:405–410
- Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK (2004) Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. *Clin Cancer Res* 10:3825–3830
- Miracca EC, Kowalski LP, Nagai MA (1999) High prevalence of p16 genetic alterations in head and neck tumours. *Br J Cancer* 81:677–683
- Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, Mineta H, Carey TE (2008) Epigenetic inactivation of galanin receptor 1 in head and neck cancer. *Clin Cancer Res* 14:7604–7613
- Momparler RL, Bovenzi V (2000) DNA methylation and cancer. *J Cell Physiol* 183:145–154
- Muñoz-Antonia T, Torrellas-Ruiz M, Clavell J, Mathews LA, Muro-Cacho CA, Báez A (2009) Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma. *Int J Otolaryngol* 2009:848695
- Nakagawa T, Pimkhaokham A, Suzuki E, Omura K, Inazawa J, Imoto I (2006) Genetic or epigenetic silencing of low density lipoprotein receptor-related protein 1B expression in oral squamous cell carcinoma. *Cancer Sci* 97:1070–1074
- Nakahara Y, Shintani S, Mihara M, Ueyama Y, Matsumura T (2001) High frequency of homozygous deletion and methylation of p16 (INK4A) gene in oral squamous cell carcinomas. *Cancer Lett* 163:221–228
- Nakahara Y, Shintani S, Mihara M, Hino S, Hamakawa H (2006) Detection of p16 promoter methylation in the serum of oral cancer patients. *Int J Oral Maxillofac Surg* 35:362–365
- Nakajima T, Enomoto S, Ushijima T (2008) DNA methylation: a marker for carcinogen exposure and cancer risk. *Environ Health Prev Med* 13:8–15
- Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, Irie T, Tachikawa T, Amagasa T, Inazawa J, Imoto I (2008) Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. *Cancer Sci* 99:1390–1400
- Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S, Jiang WW, Koch W, Westra W, Sidransky D, Califano J (2007) Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. *Laryngoscope* 117:1376–1380
- Niemhom S, Kitazawa S, Kitazawa R, Maeda S, Leopairat J (2008) Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. *Cancer Detect Prev* 32:127–134
- Nishimine M, Nakamura M, Kishi M, Okamoto M, Shimada K, Ishida E, Kirita T, Konishi N (2003) Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. *Oncol Rep* 10:555–560

- Ogane S, Onda T, Takano N, Yajima T, Uchiyama T, Shibahara T (2009) Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma. *Int J Cancer* 124:2651–2657
- Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, Sonoda T, Kohama G, Tokino T (2002) Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. *Clin Cancer Res* 8:3164–3171
- Ohshima H, Tazawa H, Sylla BS, Sawa T (2005) Prevention of human cancer by modulation of chronic inflammatory processes. *Mutat Res* 591:110–122
- Ohta S, Uemura H, Matsui Y, Ishiguro H, Fujinami K, Kondo K, Miyamoto H, Yazawa T, Danenberg K, Danenberg PV, Tohrai I, Kubota Y (2009) Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 107:81–91
- Okada Y, Yamazaki H, Sekine-Aizawa Y, Hirokawa N (1995) The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. *Cell* 81:769–780
- Okami K, Sakai A, Onuki J, Hamano T, Iida M, Takahashi M (2005) Promoter hypermethylation of tumor-associated genes in head and neck cancer. *Nippon Jibiinkoka Gakkai Kaiho* 108:207–213
- Olasz J, Juhász A, Remenár E, Engi H, Bak M, Csuka O, Kásler M (2007) RAR beta2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age. *Oncol Rep* 18:105–112
- Pattani KM, Zhang Z, Demokan S, Glazer C, Loyo M, Goodman S, Sidransky D, Bermudez F, Jean-Charles G, McCaffrey T, Padhya T, Phelan J, Spivakovsky S, Bowne HY, Goldberg JD, Rolnitzky L, Robbins M, Kerr AR, Sirois D, Califano JA (2010) Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. *Cancer Prev Res* 3:1093–1103
- Piyathilake CJ, Bell WC, Jones J, Henao OL, Heimbürger DC, Niveleau A, Grizzle WE (2005) Patterns of global DNA and histone methylation appear to be similar in normal, dysplastic and neoplastic oral epithelium of humans. *Dis Markers* 21:147–151
- Puri SK, Si L, Fan CY, Hanna E (2005) Aberrant promoter hypermethylation of multiple genes in head and neck squamous cell carcinoma. *Am J Otolaryngol* 26:12–17
- Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q (2004) The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. *Oncogene* 23:4793–4806
- Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K (2010) Nasopharyngeal carcinoma: the next challenges. *Eur J Cancer* 46:1967–1978
- Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res* 56:3630–3633
- Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC, Jiang SW (2011) DNA hypermethylation as a chemotherapy target. *Cell Signal* 23:1082–1093
- Richards KL, Zhang B, Baggerly KA, Colella S, Lang JC, Schuller DE, Krahe R (2009) Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. *PLoS One* 4:e4941
- Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, Beleites E, Claussen U, von Eggeling F (1999) Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. *Int J Mol Med* 4:61–65
- Righini CA, de Fraipont F, Timsit JF, Faure C, Brambilla E, Rey E, Favrot MC (2007) Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. *Clin Cancer Res* 13:1179–1185
- Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. *Cancer Res* 61:939–942
- Rubin H (2011) Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. *Bioessays* 33:224–231
- Ruesga MT, Acha-Sagredo A, Rodríguez MJ, Aguirregaviria JI, Videgain J, Rodríguez C, de Pancorbo ML, Aguirre JM (2007) p16(INK4a) promoter hypermethylation in oral scrapings of oral squamous cell carcinoma risk patients. *Cancer Lett* 250:140–145
- Sailasree R, Abhilash A, Sathyan KM, Nalinakumari KR, Thomas S, Kannan S (2008) Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. *Cancer Epidemiol Biomarkers Prev* 17:414–420
- Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC, Tada K, Ong WY, Soong R, Voon DC, Ito Y (2006) RUNX3 protein is overexpressed in human basal cell carcinomas. *Oncogene* 25:7646–7649
- Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. *Cancer Res* 60:892–895
- Scully C, Field JK, Tanzawa H (2000) Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. *Oral Oncol* 36:256–263
- Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q (2007) The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. *Oncogene* 26:934–944
- Sengupta S, Chakrabarti S, Roy A, Panda CK, Roychoudhury S (2007) Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype. *Cancer* 109:703–712
- Sharma R, Panda NK, Khullar M (2010) Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer. *Oral Dis* 16:668–673
- Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM (2006) Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. *Br J Cancer* 94:561–568
- Shaw RJ, Omar MM, Rokadiya S, Kogera FA, Lowe D, Hall GL, Woolgar JA, Homer J, Liloglou T, Field JK, Risk JM (2009) Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. *Br J Cancer* 101:139–144
- Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. *J Natl Cancer Inst* 97:1330–1338
- Shiah SG, Chang LC, Tai KY, Lee GH, Wu CW, Shieh YS (2009) The involvement of promoter methylation and DNA methyltransferase-1

- in the regulation of EpCAM expression in oral squamous cell carcinoma. *Oral Oncol* 45:e1–e8
- Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T (2001) Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. *Oral Oncol* 37:498–504
- Sinha P, Bahadur S, Thakar A, Matta A, Macha M, Ralhan R, Gupta SD (2009) Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. *Head Neck* 31:1423–1430
- Smigiel R, Sasiadek M, Krecicki T, Ramsey D, Jagielski J, Blin N (2004) Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. *Mol Carcinog* 39:147–154
- Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA, Morrison CD, Smiraglia DJ, Plass C (2006) Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23–q24 in lung and head and neck cancer. *Proc Natl Acad Sci USA* 103:982–987
- Smith IM, Mydlarz WK, Mithani SK, Califano JA (2007) DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. *Int J Cancer* 121:1724–1728
- Smith IM, Mithani SK, Mydlarz WK, Chang SS, Califano JA (2010) Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers. *ORL J Otorhinolaryngol Relat Spec* 72:44–50
- Smollich M, Wülfing P (2008) Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. *Expert Rev Anticancer Ther* 8:1481–1493
- Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, Sasaki Y, Hiratsuka H, Tokino T (2008) Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. *Int J Oncol* 32:1253–1261
- Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH (2009) Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. *Oncol Rep* 22:1519–1526
- Subbalekha K, Pimkhaokham A, Pavasant P, Chindavijak S, Phokaew C, Shuangshoti S, Matangkasombut O, Mutirangura A (2009) Detection of LINE-1s hypomethylation in oral rinses of oral squamous cell carcinoma patients. *Oral Oncol* 45:184–191
- Sun D, Zhang Z, Van do N, Huang G, Emberg I, Hu L (2007) Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. *Oral Oncol* 43:82–87
- Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK, Califano JA (2010) TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. *Clin Cancer Res* 16:857–866
- Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB (2004) Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. *Nat Genet* 36:417–422
- Suzuki E, Imoto I, Pimkhaokham A, Nakagawa T, Kamata N, Kozaki KI, Amagasa T, Inazawa J (2007) PRFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. *Oncogene* 26:7921–7932
- Szpakowski S, Sun X, Lage JM, Dyer A, Rubinstein J, Kowalski D, Sasaki C, Costa J, Lizardi PM (2009) Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. *Gene* 448:151–167
- Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ (2001) Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. *Clin Cancer Res* 7:1523–1532
- Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, Braakhuis BJ (2002) Multiple head and neck tumors frequently originate from a single preneoplastic lesion. *Am J Pathol* 161:1051–1060
- Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ (2004) Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. *Clin Cancer Res* 10:3607–3613
- Taioli E, Ragin C, Wang XH, Chen J, Langevin SM, Brown AR, Gollin SM, Garte S, Sobol RW (2009) Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. *BMC Cancer* 9:354
- Takeshima M, Saitoh M, Kusano K, Nagayasu H, Kurashige Y, Malsantha M, Arakawa T, Takuma T, Chiba I, Kaku T, Shibata T, Abiko Y (2008) High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. *J Oral Pathol Med* 37:475–479
- Tan SH, Ida H, Goh BC, Hsieh W, Loh M, Ito Y (2006) Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. *Anticancer Res* 26:4287–4292
- Tan HK, Saulnier P, Auperin A, Lacroix L, Casiraghi O, Janot F, Fouret P, Temam S (2008) Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas. *Br J Cancer* 99:357–363
- Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Noshio K, Adachi Y, Endo T, Imai K, Shinomura Y (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. *Oncogene* 24:7946–7952
- Tao J, Wu B, Fang W (1997) Mutation and methylation of CDKN2 gene in human head and neck carcinomas. *Zhonghua Bing Li Xue Za Zhi* 26:152–154
- Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, Hoque MO, Westra WH, Califano JA, Sidransky D (2004) Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. *Cancer Res* 64:5982–5987
- Tokumaru Y, Yahata Y, Fujii M (2005) Aberrant promoter hypermethylation of tazarotene-induced gene 1 (TIG1) in head and neck cancer. *Nippon Jibiinkoka Gakkai Kaiho* 108:1152–1157
- Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D (2008) The role of PGP9.5 as a tumor suppressor gene in human cancer. *Int J Cancer* 123:753–759
- Tong JH, Ng DC, Chau SL, So KK, Leung PP, Lee TL, Lung RW, Chan MW, Chan AW, Lo KW, To KF (2010) Putative tumour-suppressor gene DAB2 is frequently downregulated by promoter hypermethylation in nasopharyngeal carcinoma. *BMC Cancer* 10:253
- Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T (2003) Epigenetic inactivation of CHFR in human tumors. *Proc Natl Acad Sci USA* 100:7818–7823
- Tsao SW, Liu Y, Wang X, Yuen PW, Leung SY, Yuen ST, Pan J, Nicholls JM, Cheung AL, Wong YC (2003) The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. *Eur J Cancer* 39:524–531
- Tsunematsu T, Kudo Y, Iizuka S, Ogawa I, Fujita T, Kurihara H, Abiko Y, Takata T (2009) RUNX3 has an oncogenic role in head and neck cancer. *PLoS One* 4:e5892
- Uchida D, Begum NM, Almofti A, Kawamata H, Yoshida H, Sato M (2004) Frequent downregulation of 14-3-3 sigma protein and

- hypermethylation of 14-3-3 sigma gene in salivary gland adenoid cystic carcinoma. *Br J Cancer* 91:1131–1138
- Ushijima T (2007) Epigenetic field for cancerization. *J Biochem Mol Biol* 40:142–150
- Viswanathan M, Tsuchida N, Shanmugam G (2003) Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. *Int J Cancer* 105:41–46
- Wagner JM, Hackanson B, Lübbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. *Clin Epigenetics* 1:117–136
- Wang T, Liu H, Chen Y, Liu W, Yu J, Wu G (2009) Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. *J Exp Clin Cancer Res* 28:160
- Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A (2002) INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. *Virchows Arch* 441:133–142
- Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A (2005) SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. *Oncogene* 24:6699–6708
- Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK (2006) Implications of methylation patterns of cancer genes in salivary gland tumors. *Clin Cancer Res* 12:7353–7358
- Wong TS, Chang HW, Tang KC, Wei WI, Kwong DL, Sham JS, Yuen AP, Kwong YL (2002) High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. *Clin Cancer Res* 8:433–437
- Wong TS, Kwong DL, Sham JS, Tsao SW, Wei WI, Kwong YL, Yuen AP (2003a) Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. *Clin Cancer Res* 9:3042–3046
- Wong TS, Tang KC, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP (2003b) Differential gene methylation in undifferentiated nasopharyngeal carcinoma. *Int J Oncol* 22:869–874
- Worsham MJ, Chen KM, Stephen JK, Havard S, Benninger MS (2010) Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer. *Otolaryngol Head Neck Surg* 143:116–121, 121.e1–121.e19
- Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR (2006) Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. *J Natl Cancer Inst* 98:181–189
- Yakushiji T, Noma H, Shibahara T, Arai K, Yamamoto N, Tanaka C, Uzawa K, Tanzawa H (2001) Analysis of a role for p16/CDKN2 expression and methylation patterns in human oral squamous cell carcinoma. *Bull Tokyo Dent Coll* 42:159–168
- Yalniz Z, Demokan S, Suoglu Y, Uluhan M, Dalay N (2011) Simultaneous methylation profiling of tumor suppressor genes in head and neck cancer. *DNA Cell Biol* 30:17–24
- Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D (2002) Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. *Cancer Cell* 2:485–495
- Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. *Clin Cancer Res* 12:6626–6636
- Yanatatsanejit P, Chalermchai T, Kerekhanjanarong V, Shotelersuk K, Supiyaphun P, Mutirangura A, Sriuranpong V (2008) Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma. *Oral Oncol* 44:400–406
- Yeh KT, Shih MC, Lin TH, Chen JC, Chang JY, Kao CF, Lin KL, Chang JG (2002) The correlation between CpG methylation on promoter and protein expression of E-cadherin in oral squamous cell carcinoma. *Anticancer Res* 22:3971–3975
- Yeh KT, Chang JG, Lin TH, Wang YF, Tien N, Chang JY, Chen JC, Shih MC (2003) Epigenetic changes of tumor suppressor genes, P15, P16, VHL and P53 in oral cancer. *Oncol Rep* 10:659–663
- Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M, Yao KT, Ren CP (2006) Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. *Oncol Res* 16:261–272
- Yi HM, Ren CP, Peng D, Zhou L, Li H, Yao KT (2007) Expression, loss of heterozygosity, and methylation of GNAT1 gene in nasopharyngeal carcinoma. *Ai Zheng* 26:9–14
- Yi B, Tan SX, Tang CE, Huang WG, Cheng AL, Li C, Zhang PF, Li MY, Li JL, Yi H, Peng F, Chen ZC, Xiao ZQ (2009) Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. *J Cell Biochem* 106:858–866
- Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. *Oncogene* 25:1070–1080
- Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman SM, Hong WK, Lotan R (2004) Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. *Clin Cancer Res* 10:1733–1742
- Zhang S, Kong WJ (2004) Hypermethylation of the death-associated protein kinase promoter in laryngeal squamous cell cancer. *Zhonghua Zhong Liu Za Zhi* 26:469–471
- Zhang S, Kong WJ, Liu Z (2004) Promoter hypermethylation of DNA repair gene O6-methylguanine DNA methyltransferase in laryngeal squamous cell carcinoma. *Zhonghua Er Bi Yan Hou Ke Za Zhi* 39:152–156
- Zhang S, Guo C, Kong W, Liu Z (2006) Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. *J Huazhong Univ Sci Technolog Med Sci* 26:101–104
- Zhang CY, Mao L, Li L, Tian Z, Zhou XJ, Zhang ZY, Li J (2007a) Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. *Cancer* 110:87–95
- Zhang Z, Sun D, Van do N, Tang A, Hu L, Huang G (2007b) Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. *Int J Cancer* 120:32–38
- Zhou L, Jiang W, Ren C, Yin Z, Feng X, Liu W, Tao Q, Yao K (2005) Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein–Barr virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. *Neoplasia* 7:809–815
- Zhou L, Feng X, Shan W, Zhou W, Liu W, Wang L, Zhu B, Yi H, Yao K, Ren C (2007) Epigenetic and genetic alterations of the EDNRB gene in nasopharyngeal carcinoma. *Oncology* 72:357–363
- Zhou W, Feng X, Li H, Wang L, Zhu B, Liu W, Zhao M, Yao K, Ren C (2009) Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. *Acta Biochim Biophys Sin (Shanghai)* 41:54–62
- Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP, Fan CY (2004) O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 13:967–975
- Zuo C, Zhang H, Spencer HJ, Vural E, Suen JY, Schichman SA, Smoller BR, Kokoska MS, Fan CY (2009) Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma. *Otolaryngol Head Neck Surg* 141:484–490